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Abstract 
Disease burden of infectious diseases in Europe: a pilot study 
 
Consequences of different infectious diseases cannot be adequately compared with each other 
on the basis of the number of patients or mortality data only. It is better to combine all health 
effects and express the total impact as disease burden, which also takes duration and severity 
of diseases into account. Information on disease burden also helps to set priorities in 
European policy for infectious disease control. 
 
In a pilot study, the disease burden of seven infectious diseases in Europe has been estimated. 
In spite of various limitations with regard to availability and quality of data, it was found that 
HIV infection, tuberculosis and influenza cause, among the selected infectious diseases, the 
highest disease burden in Europe. Foodborne diseases caused by the bacteria Campylobacter 
spp., enterohaemorrhagic Escherichia coli and Salmonella spp. and, in particular, measles, 
are associated with a lower burden. 
 
The current disease burden of infectious diseases reflects the balance between the disease 
threats and the effectiveness of preventive strategies. A low burden stresses the need for the 
continued support of these strategies, while a high burden indicates the need for additional 
interventions. Based on this pilot, the RIVM recommends that a full burden of disease 
study - combining several methods of investigation - be conducted in cooperation with 
different European institutes. 
 
 
Key words: disease burden; priority setting; infectious diseases; Disability Adjusted 
                   Life Year; DALY; Europe 
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Rapport in het kort 
Ziektelast van infectieziekten in Europa: een pilot studie 
 
De gevolgen van verschillende infectieziekten zijn onderling niet goed te vergelijken op basis 
van het aantal patiënten of sterftecijfers alleen. Het is beter om alle gezondheidseffecten te 
combineren en de totale impact uit te drukken in ziektelast, dat ook rekening houdt met duur 
en ernst van ziekten. Informatie over ziektelast helpt prioriteiten te stellen in het Europese 
beleid op het gebied van infectieziektebestrijding.  
 
In een pilotstudie is de ziektelast geschat van zeven infectieziekten in Europa. Ondanks 
verschillende beperkingen in beschikbaarheid en kwaliteit van gegevens wordt geschat dat 
HIV-infectie, tuberculose en influenza van de geselecteerde infectieziekten de grootste 
ziektelast in Europa veroorzaken. Voedseloverdraagbare ziekten die worden veroorzaakt door 
de bacteriën Campylobacter spp., enterohemorragische Escherichia coli en Salmonella spp., 
en mazelen in het bijzonder, zijn geassocieerd met een lagere ziektelast.  
 
De huidige ziektelast van de infectieziekten weerspiegelt de balans tussen bedreigingen van 
de ziekten en effectiviteit van preventiemaatregelen. Een lage ziektelast benadrukt de 
noodzaak van voortdurende ondersteuning van deze maatregelen, een hoge ziektelast duidt 
erop dat aanvullende acties nodig zijn. Op basis van deze pilotstudie adviseert het RIVM om 
samen met verschillende Europese instituten een uitgebreidere studie uit te voeren, die 
verschillende onderzoeksmethoden combineert.  
 
 
Trefwoorden: ziektelast; prioritering; infectieziekten; Disability Adjusted Life Year; DALY; 
Europa 
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Summary 
Background 
The European Centre for Disease Prevention and Control (ECDC) has a responsibility to 
identify, assess and communicate current and emerging threats to human health from 
infectious diseases. As one of the elements to fulfil the above responsibility, the ECDC is 
producing the Annual Epidemiological Report on Communicable Diseases for 2005. The aim 
of this report is to give a comprehensive overview of the threat of infectious diseases in the 
European Union in 2005. The report analyses incidence trends and patterns of the 46 diseases 
under mandatory surveillance, together with SARS, avian influenza and West Nile virus. The 
trends identified give one indication of which diseases require priority action, and including 
mortality, prevalence (very little data) and sequelae would give additional indications. 
However, such assessments, if used individually, make it difficult to get an overall 
assessment of disease burden, as the diseases and their consequences are heterogeneous in 
terms of mortality and morbidity.  
 
Composite health measures attempt to overcome those issues by combining mortality, 
incidence (and/or prevalence) and the sequelae due to an infectious agent. ECDC wishes to 
evaluate whether a composite measure could be useful to inform its decision making process. 
If successful, then the composite measure could be used as one element to gain insight in 
(expected) trends to guide public health policy and actions within the group of 49 infectious 
diseases. Several composite measures of disease burden have been developed and are 
increasingly used, including Disability Adjusted Life Years (DALYs). It is important to 
remember that absolute values of such measures (be they DALYs or any other) are of little 
significance. It is only their relative values that are important in indicating and guiding public 
health policy and action. Furthermore, disease burden is only one of the criteria that can be 
used for priority setting. Other priority setting criteria are incidence, severity, potential to 
spread among the general population, socioeconomic burden, preventability, potential to 
drive public health policy, risk perception, changing patterns in time1 and outbreak potential. 
 
As a first step, a pilot study was carried out to illustrate the potential of the disease burden 
concept, to explore data availability and quality, to recommend future studies and to stimulate 
debate. This study was conducted in a short period of time to fit into the time schedule of the 
production of ECDC’s Annual Epidemiological Report on Communicable Diseases for 2005. 
Due to time and resource limitations, it was decided to only include generally available data 
such as those of Eurostat, WHO and dedicated surveillance networks. Seven diseases were 
included in this pilot: influenza, measles, infection with Human Immunodeficiency Virus 
(HIV-infection), campylobacteriosis, infection with enterohaemorrhagic Escherichia coli 
(EHEC-infection), salmonellosis and tuberculosis. These diseases were mainly selected based 
on the availability of incidence and mortality data and previous experience at RIVM so that 
comparisons could be made. 
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It is recognised that the results of this initial study, based on generally available information, 
do not reflect the full disease burden of the selected infectious diseases in Europe, due to 
potential underreporting in the available data on morbidity and mortality. Also, as the extent 
of the potential underreporting varies between different diseases (and countries), even the 
current relative comparisons of disease burden could be biased. Furthermore, not all relevant 
outcomes could be included in this preliminary assessment. To explore the uncertainty 
resulting from those limitations, scenario analyses were carried out and the disease burden 
estimates were compared with those of previously published more detailed studies.  
 
Methods 
The DALY methodology has been described by Murray and co-workers in the Global Burden 
of Disease (GBD) project,2, 3 using the following equation: 
    DALY = YLL + YLD. 
YLL is the number of years of life lost due to mortality and YLD is the number of years lived 
with a disability, weighted with a factor between 0 and 1 for the severity of the disability. The 
YLL due to a specific disease in a specified population is calculated by summation of all fatal 
cases (d) due to the health outcomes (l) of a specific disease, each case multiplied by the 
expected individual life span (e) at the age of death: 
 ∑ ×=
l
ll edYLL
  
YLD is calculated by the product of the duration of the illness (t) and the severity weight (w) 
of a specific disease, accumulated over all cases (n) and all health outcomes (l): 
 ∑ ××=
l
lll wtnYLD
  
Applying the DALY methodology involves making several choices on details of the analysis 
which should reflect value choices that are relevant to the decision maker. For this pilot 
project, the choices were made (in many cases due to pragmatic reasons coming from the 
three months duration of this pilot) in consultation with staff members of ECDC: 
- incidence approach (in contrast to prevalence approach) 
- agent-based approach (in contrast to outcome-based approach) 
- selection of outcomes to be included in the outcome tree for each of the diseases 
- European life expectancy (in contrast to life expectancy from a standard life table) 
- no application of discounting and age-weighting 
- severity weights based on period profile if available (in contrast to annual profile) 
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Data sources and limitations  
Depending on data availability, as many as possible member states of the European Union 
and EEA/EFTA* countries were included. Generally available data have been derived from: 
YLL d = Number of fatal cases : Mean number of deaths 2003-2004 reported to Eurostat/WHO 
 e = Life expectancy at age of death : European life expectancy 2004 
YLD n = Number of cases of illness : Mean incidence 2003-2005 reported to 
- EuroHIV (HIV-infection) 
- EuroTB (tuberculosis) 
- EISS (influenza, mean 2002/2003-2004/2005) 
- Eurostat (other diseases) 
 t = Duration of illness : Literature (mainly Global Burden of Disease study) 
 w = Severity weights : Literature (mainly Global Burden of Disease study)  
 
Major limitations in data availability were: 
• inconsistent morbidity and/or mortality by some countries and/or for some years; 
• very limited information on the age-distribution of morbidity for most diseases; 
• no reporting of the incidence of complications and chronic sequelae; 
• no consistent set of severity weights available. 
 
Major limitations with regard to data quality were: 
• no information on underreporting of morbidity and mortality; 
• no information on possible variation between countries of the duration, severity and rate of 
complications and chronic sequelae; 
• differences between reports from different sources (national, Eurostat and WHO).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* European Economic Area (EEA) / European Free Trade Association (EFTA)
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Results  
This study makes clear that the relative burden of diseases as measured by disease burden is 
quite different compared to the relative burden as measured by just incidence or mortality 
data (Figure 1). Based on incidence data individually, the foodborne diseases cause relatively 
the greatest burden, while mortality data indicate the relatively high burden of tuberculosis. 
Disease burden (DALYs) shows a quite different picture with a relative high burden for HIV-
infection and tuberculosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Relative burden of the seven selected diseases based on different indicators: 
- incidence (mean number of reported new cases per year in the period 2003-2005) 
- mortality (mean number of reported deaths per year in the period 2003-2004) 
- disease burden (DALYs per year based on above mentioned incidence and mortality) 
influenza measles HIV-infection campylobacteriosis EHEC-infection salmonellosis tuberculosis
disease burden
4.7% 0.5%
38.3%
10.7%3.5%
6.3%
35.9%
incidence
2.2%
0.3%
3.9%
42.5%
3.0%
38.8%
9.3%
mortality
14.9%
0.3%
23.4%
0.1%
0.0%
2.0%
59.3%
Based on data for twelve countries (data available for all seven diseases): 
Austria Ireland the Netherlands  Sweden 
Czech Republic Latvia  Poland  United Kingdom 
Germany Lithuania Slovenia  Norway 
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-> ranges from 0 in Cyprus to 27.6 in Czech Republic
-> ranges from 0 in Cyprus to 8.7 in Czech Republic
-> ranges from 0.4 in Portugal  to 19.1 in Czech Republic
-> ranges from 3.4 in Malta to 263.2 in Lithuania
In Figure 2 an estimate of the total disease burden per 100,000 population for the seven 
selected diseases is shown, for those countries for which YLD and YLL and DALY could be 
calculated. An analysis based on twelve countries for which the disease burden could be 
calculated for all diseases, shows a quite similar picture (see Appendix V). HIV-infection and 
tuberculosis have the highest disease burden in Europe, measles the lowest.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Sum of disease burden per 100,000 population of all countries for which data are 
available for at least one disease (for each disease number of countries is different) 
(Table 3.1 shows per disease which countries could not be included) 
 
For the Netherlands comparisons with more extensive studies (Figure 3) and results from 
scenario analysis have suggested that the disease burden of influenza is seriously 
underestimated (especially morbidity). Especially for HIV-infection the information on long-
term outcomes of current infections and the effect of Highly Active Anti-Retroviral Therapy 
(HAART) is incomplete. Furthermore, morbidity and in particular mortality of foodborne 
diseases (campylobacteriosis, EHEC-infection and salmonellosis) were likely to be 
underestimated due to underreporting. Estimates of the burden of measles and tuberculosis 
appear to be less uncertain. 
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Figure 3 Comparison of results from the pilot study for the Netherlands with previously published 
more extensive (Dutch) studies 
 
Conclusions 
The relative burden of diseases as measured by disease burden is quite different compared to 
the relative burden as measured by just incidence or mortality data. Taking into account the 
limitations in data availability and quality, it was found that (based on data for 2003-2005 
when available) the disease burden in Europe is estimated to be highest for HIV-infection and 
tuberculosis, followed by campylobacteriosis, influenza and salmonellosis, and was lowest 
for measles and EHEC-infection. Scenario analysis limited to the Netherlands suggested that 
this ranking is not likely to be affected by better data. However, the relative burden of 
influenza is likely to increase. It must be noted that differences between countries sometimes 
are considerable and may be due to differences in reporting. 
The current disease burden reflects the balance between threats and the effectiveness of 
preventive strategies. A low burden stresses the need for the continued support of these 
strategies. A high burden indicates the need for additional interventions. Disease burden 
estimates provide an integrated representation of the burden of infectious diseases. However, 
for priority setting other factors, such as threats and trends, costs and perception should be 
taken into account as well.  
 
pilot = pilot study on behalf of ECDC (data 2003-2005; agent approach) 
GBD = Global Burden of Disease study conducted by WHO (data 2002; outcome approach);  
PHSF = Public Health Status and Forecast studies conducted by RIVM for the Netherlands (data 2003; outcome approach); 
RIVM = extensive studies on foodborne pathogens conducted by RIVM for the Netherlands (data 2004; agent approach)
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Recommendations 
Disease burden (DALYs) calculations should be extended to other infectious diseases as well, 
because this composite measure gives more insight in burden than incidence or mortality data 
on its own. A full burden of disease study is recommended and would benefit from an 
approach that combines and triangulates several methods of investigation, including 
epidemiological modelling. In this short term pilot pragmatic choices had to be made, a full 
study should include a systematic and critical review on other disease burden estimates and 
on aspects like most suitable data sources, extent of underreporting, severity weights, 
outcome trees etcetera for each of the diseases under study.  Furthermore there needs to be 
general agreement on methodological issues discussed in Chapter 2 like using a standard life 
table instead of the European life expectancy (that changes over time) or showing both 
discounted and undiscounted results in the future. Where possible a full burden of disease 
study should join other international efforts in this field (i.e. the WHO update of the Global 
Burden of Disease for the year 2004). With regard to priority setting, besides disease burden 
other aspects such as economical costs or outbreak potential should also be taken into 
account. 
 
In order to obtain better insight in the epidemiology of infectious diseases in general and in 
the disease burden in particular, the following recommendations are made: 
• improve the completeness and consistency of reporting of the incidence of morbidity and 
mortality in Europe, including information on the age-distribution; 
• conduct cohort studies on the incidence of complications and chronic sequelae, including 
possible variability between countries and factors associated with that variability; 
• conduct studies addressing sources of underreporting of morbidity and mortality in order 
to calibrate the data and to decrease inconsistencies in reporting between countries; 
• improve quantification of the mortality risks due to infectious diseases by cohort-studies; 
• integrate mathematical modelling to better understand the current and future burden, in 
particular for the HIV/AIDS epidemic including the impact of HAART; 
• promote standardized data collection on disease severity and duration across Europe; 
• conduct studies on severity weights and obtain consensus on the protocols for such 
studies, including national differences; 
• develop a standardized approach to value choices inherent in disease burden calculations. 
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1. Introduction 
 
The European Centre for Disease Prevention and Control (ECDC) has a responsibility to 
identify, assess and communicate current and emerging threats to human health from 
infectious diseases. As one of the elements to fulfil the above responsibility, the ECDC is 
producing the Annual Epidemiological Report on Communicable Diseases for 2005. The aim 
of this report is to give a comprehensive overview of the threat of infectious diseases in the 
European Union in 2005. The report analyses incidence trends and patterns of the 46 diseases 
under mandatory surveillance, together with SARS, avian influenza and West Nile virus for 
the different countries (Appendix I and II). The trends identified give one indication of which 
diseases require priority action, and including mortality, prevalence (very little data) and 
sequelae would give additional indications. However, such assessments if used individually 
make it difficult to get an overall assessment of disease burden, as the diseases and their 
consequences are heterogeneous in terms of mortality and morbidity. For example, diseases 
that do not (or seldom) result in death would not figure as high priority using mortality, 
whereas just incidence (or prevalence if such data were universally available) would 
underplay the effect of diseases with high case fatality ratios. 
 
Composite health measures (such as Disability Adjusted Life Years) attempt to overcome 
those issues by combining mortality, incidence (and/or prevalence) and the sequelae due to an 
infectious agent. ECDC wishes to evaluate whether a composite measure could be useful to 
inform its decision making process. If successful, then the composite measure could be used 
as one element to gain insight in (expected) trends to guide public health policy and actions 
within the group of 49 infectious diseases. Several composite measures of disease burden 
have been developed and are increasingly used, including Disability Adjusted Life Years 
(DALYs). It is important to remember that absolute values of composite measures (be they 
DALYs or any other) are of little significance. It is only their relative values that are 
important in indicating and guiding public health policy and action. Furthermore, disease 
burden is only one of the criteria that can be used for priority setting. Other priority setting 
criteria are incidence, severity, potential to spread among the general population, 
socioeconomic burden, preventability, potential to drive public health policy, risk perception, 
changing patterns in time1 and outbreak potential. 
 
The Dutch National Institute for Public Health and the Environment (RIVM) has 
considerable experience in applying the DALY concept at the level of the Dutch population, 
dating back to the Public Health Status and Forecast study document published in 1997.4 The 
emphasis in this document was on the impact of major diseases such as cardiovascular 
disease and cancer. However, the disease burden of a number of infectious diseases has also 
been assessed.5 Further work at RIVM on infectious diseases has focussed on foodborne 
pathogens including thermophilic Campylobacter spp.6 and Shiga-toxin producing 
Escherichia coli O157.7  
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Disease burden estimates have been used for estimating the cost-effectiveness of 
interventions to reduce the contamination of broiler meat with thermophilic Campylobacter 
spp.8 and as an aspect of priority setting of foodborne pathogens.9 This latter study also 
included disease burden estimates of non-typhoidal Salmonella spp., noroviruses, rotaviruses, 
listeriosis and toxoplasmosis. Therefore, the RIVM has been invited by ECDC to perform a 
pilot study on disease burden of infectious diseases at European level.  
 
The ultimate goal is to produce an estimate of disease burden of infectious diseases at 
European level and gain insight in (expected) trends to guide public health policy and actions. 
This pilot study was carried out to illustrate the potential of the disease burden concept, to 
explore data availability and quality, to recommend future studies and to stimulate debate. 
This study was conducted in a short period of time to fit into the time schedule of the 
production of ECDC’s Annual Epidemiological Report on Communicable Diseases for 2005. 
Due to time and resource limitations, it was decided to only include generally available data 
such as those of Eurostat, WHO and dedicated surveillance networks. Given time and data 
limits, as a first step only a limited number of diseases have been assessed in a pilot, based on 
generally available information and using methodology appropriate to give results from 
existing data and within time limits of the initial stages of this work. The diseases which met 
one or more of the selection criteria (Table 1.1) were included in a pilot study. The most 
important criteria were the availability of incidence and mortality data and previous 
experience at RIVM so that comparisons could be made. 
 
Table 1.1 Selection criteria for inclusion of infectious diseases in the pilot study 
  Selected infectious diseases 
  
Criteria 
 
Influenza 
 
Measles 
HIV-
infection 
Campylo-
bacteriosis 
EHEC-
infection 
Salmo-
nellosis 
Tuber-
culosis 
a) European data on incidence 
and mortality available    
(X) X X X X X X 
b) Expected high burden of 
disease 
X  X    X 
c) Priority for additional control 
(prevention possibilities) 
X  X    X 
d) Former disease burden 
experience at RIVM 
X  X X X X X 
e) Upward trend   X X    
HIV: Human Immunodeficiency Virus; EHEC: enterohaemorrhagic Escherichia coli 
 
It is recognised that the results of this initial study do not reflect the full disease burden of the 
selected infectious diseases in Europe, due to potential underreporting in the available data on 
morbidity and mortality. Also, as the extent of the potential underreporting varies between 
different diseases (and countries), even the current relative comparisons of disease burden 
could be biased. Furthermore, not all relevant outcomes could be included in this preliminary 
assessment. To explore the uncertainty resulting from those limitations, scenario analyses 
were carried out and the results were compared with those of previously published more 
detailed studies.  
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This report presents the results of the pilot project. Chapter 2 describes the methods used. In 
Chapter 3 limitations in both data availability and data quality are discussed. Chapters 4-10 
provide information on a first estimate of the burden of disease for each of the seven selected 
infectious diseases: influenza, measles, HIV-infection, campylobacteriosis, EHEC-infection, 
salmonellosis and tuberculosis. In Chapter 11 a comparison between diseases is shown. 
Finally, Chapter 12 gives a general conclusion on the results obtained so far and 
recommendations for further work. 
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2. Methods 
 
A general trend in public health research is the use of disease burden, or the amount of health 
loss caused by diseases, as one aspect for indicating areas of priorities for actions. Infectious 
diseases typically have several possible health outcomes, ranging from acute self-limiting 
diseases to chronic disabilities or even death. These different outcomes can be combined in 
one single composite measure; the Disability Adjusted Life Years (DALYs) is one such 
measure. 
 
2.1 Disability Adjusted Life Years (DALYs) 
 
The DALY is a health gap measure that extends the concept of potential years of life lost due 
to premature death to include equivalent years of “healthy” life lost in states of less than full 
health, broadly termed disability. One DALY is thus one lost year of healthy life (WHO 
definition). The DALY methodology has been described by Murray and co-workers in the 
Global Burden of Disease (GBD) project,2, 3 using the following equation: 
    DALY = YLL + YLD. 
YLL is the number of years of life lost due to mortality and YLD is the number of years lived 
with a disability, weighted with a factor between 0 and 1 for the severity of the disability. The 
YLL due to a specific disease in a specified population is calculated by summation of all fatal 
cases (d) due to the health outcomes (l) of a specific disease, each case multiplied by the 
expected individual life span (e) at the age of death. Thus: 
 ∑ ×=
l
ll edYLL
  
YLD is calculated by the product of the duration of the illness (t) and the severity weight (w) 
of a specific disease, accumulated over all cases (n) and all health outcomes (l): 
 ∑ ××=
l
lll wtnYLD
  
Applying the DALY methodology involves making several choices on details of the analysis 
which should reflect value choices that are relevant to the decision maker. For this pilot 
project, the choices were made (in many cases due to pragmatic reasons coming from the 
three months duration of this pilot) in consultation with staff members of ECDC and are 
described below.  
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2.2 Incidence approach 
 
In the incidence-based approach to disease burden calculations, all new cases are counted and 
all health outcomes (including those in future years) are assigned to the initial event, i.e. the 
acute (symptomatic) infection. This approach contrasts with the prevalence approach, in 
which the health status of a population at a specific point of time is assessed, possibly 
followed by attribution of the prevalent diseases to etiological agents or conditions. However, 
assuming a steady state situation there should be no difference between both approaches. In 
the field of infectious diseases prevalence data are rare, so following earlier work on 
foodborne pathogens in the Netherlands the incidence approach was used in this pilot project 
as far as possible.  
 
2.3 Agent-based approach 
 
The outcome-based approach assigns the disease burden to clinically defined categories of 
diseases (ICD-codes), irrespective of their cause. This approach is mainly used to assess the 
overall public health situation in a country or region. In contrast, the agent-based approach 
focuses on all relevant health outcomes that can be attributed to one particular agent. These 
outcomes can cover different disease categories (ICD-codes). Following earlier work on 
foodborne pathogens in the Netherlands, the agent-based approach was chosen. There is a 
risk of overestimation because co-morbidity could not be taken into account. 
 
2.4 Outcome trees 
 
Infectious diseases typically have several possible health outcomes, ranging from acute self-
limiting diseases to chronic disabilities or even death. In order to assess the burden of disease 
for the different selected infectious diseases, the disease outcomes following each specific 
infectious agent had to be defined. For each infection an outcome tree has been designed in 
consultation with experts from both ECDC and RIVM; because of the short duration of the 
pilot pragmatic choices had to be made. An outcome tree represents a qualitative 
representation of the progression of disease in time by ordering relevant health states 
following infection and illustrating their conditional dependency. For infectious diseases, the 
first blocks in the tree typically represent the incidence of infection and acute illness in a 
particular period. Subsequent blocks represent the incidence of possible outcomes, including 
recovery. For late outcomes, this incidence is accumulated over the lifetime of affected 
individuals so that the link between the blocks reflects the lifetime probability of developing 
an outcome, given the previous outcome. 
 
RIVM report 215011001 page 23 of 86 
Constructing outcome trees implied making choices on which outcomes to include and which 
to exclude from the analysis. This was based on preliminary estimations of the relative 
impact of all possible outcomes on the total disease burden. Outcomes that contribute little to 
the final result (because they are extremely rare and/or because their severity is low) have not 
been included. Construction of outcome trees is usually also guided in part by data 
availability. It is an iterative process that involves reviewing the tree while the study 
progresses. For some outcomes, the causal link with the agent of concern may not be fully 
established. For example, a statistical association has been reported but this has not (yet) been 
repeated in other independent studies and/or the causal mechanism has not (yet) been 
elucidated. In that case, a professional but subjective choice was made whether or not to 
include this outcome in the baseline model.  
 
2.5 Other choices 
 
When working with the DALY concept, it is important to make clear what value choices and 
assumptions are made, especially with regard to the choice of: 
• life expectancy 
• discounting 
• age-weighting and 
• disability weighting10  
Former research pointed out for example that the combined effect of age-weighting and 
discounting is that the burden attributed to younger age groups is considerably less than it 
would have been without these value choices.10  
 
Life expectancy 
In the absence of co-morbidity, the life expectancy of fatal cases can be derived from life 
tables if the age distribution of fatalities is known. By choosing the national life expectancy 
for each country, it would mean that the death of a 40-year old person in a country with a low 
life expectancy contributes less to the European burden of disease than the death of a 40-year 
old person in a country with a high life expectancy, which is not preferable. In the Global 
Burden of Disease study, the years of life lost due to a death at a given age has been 
calculated using the life expectancy at that age in standard life tables (West Level 26) with 
life expectancy at birth fixed at 82.5 years for females and 80.0 years for males. This standard 
has been chosen to match the highest national life expectancy observed (Japanese females).11 
In Europe however the difference in life expectancy between men and women is greater and 
therefore the mean life expectancy of the 25 EU-countries in 2004 has been used (calculation 
based on total mortality and average population 2004, data Eurostat; see Appendix III).  
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Discounting 
When the principle of discounting is applied, it means that future life years are assigned less 
value than those lived today. This is based on the economic concept that one prefers benefits 
now rather than in the future.11 Discounting is disputed because its application results in a 
lower efficiency of prevention programmes.12 Therefore, some studies show both discounted 
and undiscounted results. In this pilot project discounting has not been applied. 
 
Age-weighting 
Age-weighting is applied to reflect that individuals have different roles and changing levels 
of dependency and productivity with age. Therefore it may be appropriate to consider valuing 
the time lived at a particular age unequally.11 Age-weighting is highly debated and the exact 
quantitative implementation is controversial.13, 14 In this pilot project, age-weighting has not 
been applied. 
 
Disability weighting 
Disability weighting means that each outcome of a disease is assigned a different value on a 
scale from 0 (perfect health) to 1 (death). Although it seems controversial to weigh health 
outcomes, a Dutch study on toxoplasmosis indicates that disease burden results are more 
affected by using different data sources than different severity weights.15 This is also true for 
heart failure and rheumatoid arthritis but depends on the disease under study.16 
Ideally, the severity weights used in the calculations reflect the values in the societies under 
study. The Global Burden of Disease study divides the spectrum from health to death into 
seven disability classes17 (Table 2.1).  
 
Table 2.1 Disability classes and severity weights according to the Global Burden of Disease 
study17  
Disability 
class 
Severity 
weights 
Examples 
1 0.00-0.02 Vitiligo on face, low weight 
2 0.02-0.12 Watery diarrhoea, severe sore throat, severe anaemia 
3 0.12-0.24 Infertility, rheumatoid arthritis, angina 
4 0.24-0.36 Amputation, deafness 
5 0.36-0.50 Down syndrome 
6 0.50-0.70 Depression, blindness 
7 0.70-1.00 Psychosis, dementia, quadriplegia 
 
Severity weights can be derived through different methods. Ideally, values of the general 
public are reflected in severity weights that are used to inform policy making at the national 
or international level. Weights based on elicitation panels consisting of lay persons are 
increasingly becoming available. Previous work has depended on other panels e.g. of medical 
professionals. Values from patients who actually suffer from a disease are not considered 
informative because of coping behaviour.  
RIVM report 215011001 page 25 of 86 
Different protocols are available for panel elicitation, including the standard gamble (SG), 
time trade-off (TTO), person trade-off (PTO) and visual analogue scale (VAS). All methods 
give different results (VAS > TTO > PTO > SG), but they are correlated. The SG and VAS 
are not considered informative because they are only sensitive to severe disease (SG) or very 
sensitive to mild diseases (VAS). This leads to compression at either end of the scale. The 
TTO and PTO methods are generally used. 
 
For chronic diseases, most descriptions are based on the impact of a disease in the course of a 
year. Many infectious diseases have a rapid course, and the disease burden can be assessed by 
focusing on the phase of acute disease only (period profile) or by focusing on a year in which 
an episode of acute illness is experienced (annual profile). Both methods have been used and 
using the annual profile may overvalue disability weights.18 Hence for self-limiting diseases 
of short duration, large differences may be found between these two methods (e.g. norovirus-
associated gastro-enteritis). For such diseases, using annual profiles may lead to very high 
estimates of disease burden. In this pilot study period profiles were used except for influenza 
(acute illness) for which only an annual profile was available. 
 
The international transferability of severity weights is also a matter of concern. A study in 
Western Europe concluded that there was “a reasonably high level of agreement on disability 
weights in Western European countries with the VAS and TTO methods, but a lower level of 
agreement with the PTO method”.19 However, a recent study20 concluded that “Meaningful 
differences exist in directly elicited TTO valuations of EQ-5D health states between the 
United States and United Kingdom general populations”. Hence, severity weights are ideally 
based on specific elicitations for the population under study, but this may be very difficult to 
realise for the EU or even a specific country. In this study, internationally available severity 
weights were used (mainly from the Global Burden of Disease study, see Appendix IV). 
 
2.6 Data and data analysis 
 
The impact of infectious diseases on a society can be measured at different levels, often 
represented by the “iceberg” metaphor (see Figure 2.1). The impact of illness at different 
levels of the iceberg may differ greatly, as well as the availability of data. Therefore it is 
useful to separate these different levels in burden of disease studies. The degree of 
underreporting varies greatly between diseases as well as between countries or even within 
one country in different periods. In this pilot only generally available data could be used and 
the study did not attempt to adjust for under-reporting. 
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Figure 2.1 The “iceberg” of the burden of infectious diseases in society21  
 
Depending on data availability, as many as possible member states of the European Union 
and EEA/EFTA countries (Appendix II) have been included as they are the focus of the 
activities of ECDC. To reduce the impact of short-term fluctuations, preferably a three-year 
period (2003-2005) was considered, depending on data availability. A period of three years 
instead of a period of five years has been chosen because HIV surveillance is recently 
implemented or modified in a considerable number of countries. Reported HIV-infections 
before 2003 may therefore include a considerable number of prevalent infections diagnosed 
in the past.22 Because of comparability for all diseases the period of 2003-2005 was used. To 
be able to calculate DALYs, data on mortality, incidence, duration and severity were broken 
down into different age and sex categories where possible. 
 
Number of fatal cases 
In this pilot reported mortality data of Eurostat/WHO over the period 2003-2004 have been 
used; 2005 was not yet available for many countries (mortality data were last updated in the 
first week of January 2007). The ICD-codes used for each of the diseases are described in 
Appendix IV. Mortality from infectious diseases is typically underreported in most routine 
surveillance systems. As YLL usually are an important component of the total disease 
burden, for some diseases the impact of underreporting was explored by scenario analysis. 
There was no information available about underlying causes of death.  
 
Incidence of non-fatal health outcomes 
Depending on the complexity of the outcome tree, the incidence had to be assessed for a 
varying number of non-fatal outcomes. Ideally, this task would involve the establishment of 
the incidence of one outcome at the root of the tree (e.g. acute gastro-enteritis) and the 
(conditional) probability of progressing to the next stage or to recovery. However, such data 
were not available for the complete trees and supplementary data were necessary. These 
included the direct use of surveillance data or special studies for the incidence of the specific 
outcomes. The incidence data should ideally also be differentiated according to different 
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levels of the iceberg: non-consulting cases, cases who consult a general practitioner and 
hospitalised cases. In this order, data availability may be expected to increase, but will 
seldom be complete. An estimate of the degree of underreporting and of possible biases (from 
special studies) in the data is necessary. Such probabilities may be available from cohort or 
outbreak studies. Alternatively, the incidence may be calculated from independent 
surveillance data or special projects in the incidence of the (late) outcome of concern, and the 
attributable fraction for the agent of concern. Note that these two approaches are only 
equivalent in a stable situation, if this cannot be assumed, some kind of back-calculation 
should be applied. 
Ideally, data are available for all relevant levels of the iceberg. In this pilot project, only 
surveillance data generally available from Eurostat (last update from the website in the first 
week of January 2007), EuroHIV (provided in October 2006), EuroTB (provided in March 
2007) and EISS (based on annual reports) have been used. No information was available on 
the sensitivity of these surveillance systems for different levels of the iceberg, nor on the 
differences between countries. Data included all incident cases in a country in the chosen 
time period 2003-2005, including travel-related cases.  
 
Duration and severity of non-fatal health outcomes 
Duration of non-fatal health outcomes and severity weights have been derived from different 
publications, such as the Global Burden of Disease study,17, 23 the Public Health Status and 
Forecast studies for the Netherlands,24 former experience at RIVM9 and review articles (see 
Appendix IV). 
 
Data analysis 
For each country and each disease the disease burden or Disability Adjusted Life Years 
(DALYs per year) have been calculated using spreadsheets. Data are presented from a 
societal perspective (DALYs per year per country and per 100,000 population per country) 
and from an individual perspective (DALYs per year per individual case).  
 
If possible, the disease burden estimates in this pilot have been compared with estimates 
derived from more extensive studies: 
• The Global Burden of Disease study conducted by WHO (data 2002; outcome approach): 
extensive study on disease burden in general (both non-infectious and infectious diseases) 
that includes estimates of duration and severity of different outcomes.25 
• The Public Health Status and Forecast studies conducted by the RIVM for the Netherlands 
(data 2003; outcome approach): in this study the emphasis is on the impact of major 
diseases such as cardiovascular disease and cancer, however the disease burden of a 
number of infectious diseases has also been assessed.26 
• More extensive studies on disease burden of foodborne pathogens conducted by the RIVM 
for the Netherlands (data 2004; agent approach): in this study campylobacteriosis, EHEC-
infection, salmonellosis, noroviruses, rotaviruses, listeriosis and toxoplasmosis were 
included.9 
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Different types of uncertainty existed in the available data. These consisted of: 
• statistical uncertainty (small sample size) 
• systematic uncertainty (representativeness) 
• lack of data 
No formal uncertainty analysis was performed in this pilot project. Scenario analysis was 
employed to explore the impact of uncertain factors or assumptions in the calculations. 
Within the scope of this pilot, it was only possible to conduct a scenario analysis for the 
Netherlands. In addition, there is typically a large degree of variability in the model 
parameters. Variability may reflect different courses of the disease in different individuals, 
seasonal or multi-annual differences in incidence, differences in the values attached by 
individuals to disease outcomes etcetera. This variability was not formally included in the 
project, and arithmetic mean values were used as point estimates. 
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3. Limitations 
 
For the baseline disease burden estimates a number of limitations regarding data availability 
and data quality were identified which should be kept in mind when interpreting the results of 
this pilot study. Some limitations were addressed by scenario analysis. 
 
3.1 Data availability 
Incidence 
- Data on incidence of the acute illness were not available for all countries for all years  
-> YLD (and DALY) have not been calculated for those countries with no information at all 
(see Table 3.1) 
-> YLD was based on the mean incidence for countries with data available for 1, 2 or 3 years 
- Data on incidence of most of the complications were not available 
(except for AIDS and multidrug-resistant tuberculosis) 
-> The probability of most complications has been based on (Dutch) literature and previous 
     experience at RIVM 
 
Duration and severity weights 
- For most diseases the incidence data were not age-specific 
(except for HIV-infection and tuberculosis)  
-> For duration of chronic conditions (= remaining life expectancy) a proxy has been taken 
    (e.g. for the measles outcome “deafness due to otitis media” full life expectancy was taken 
     as a proxy because in general incidence of measles is highest in the youngest age groups) 
-> In case of age-specific severity weights a proxy has been taken 
    (e.g. for the measles outcome “deafness due to otitis media” the mean severity weight for 
     the youngest age groups 00-04 year and 05-14 year has been taken)    
- Not for all different outcomes of all diseases information on duration and severity weights 
was available 
-> In case of lack of information a similar outcome has been chosen as a proxy 
 
Mortality 
- Data on mortality were not available for all countries  
-> YLL (and DALY) have not been calculated for those countries (see Table 3.1) 
 
Life expectancy 
- There was no recent European life expectancy generally available  
-> A calculation based on Eurostat data for 2004 has been used 
    (total mortality + average population 2004 of the EU-25 countries) 
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Table 3.1 Countries for which the disease burden could not be calculated 
DATA influenza measles HIV-
infection 
campylo-
bacteriosis 
EHEC-
infection 
salmonellosis tuberculosis 
NO 
YLD 
Cyprus 
Estonia 
Finland 
Greece 
Hungary 
Iceland 
Liechtenstein 
Malta 
Liechtenstein Cyprus 
Liechtenstein 
Spain 
Greece 
Liechtenstein 
Luxembourg
Portugal 
Belgium 
France 
Italy 
Liechtenstein 
Luxembourg
Portugal 
Liechtenstein Liechtenstein 
NO 
YLL 
Belgium 
Denmark 
Italy 
Liechtenstein  
Slovakia 
HIV: Human Immunodeficiency Virus; EHEC: enterohaemorrhagic Escherichia coli 
 
3.2 Data quality 
Incidence 
- There was no information on the sensitivity of the different surveillance systems 
(tip of the iceberg) 
- There was no information on the case definition of incidence data from Eurostat 
- Incidence data were not always available for whole countries (only for some regions within a 
country) and extrapolation was not possible 
- There was no information on variation in complication rates between countries, a constant 
complication rate was assumed 
- Incidence provided by Eurostat is not always identical to national incidence 
 
Duration and severity weights 
- The duration and severity weights have been derived from different literature sources, so 
there is no consistency in the used methodology 
- There was no differentiation in duration and severity possibly related to need of medical care 
- There was no information on variation between countries 
(for some outcomes GBD duration data differ between Established Market Economies, 
Formerly Socialist Economies and Middle Eastern Crescent)  
- Duration and severity could not be based on recent literature which means that for example 
for HIV-infection HAART could not be taken into account 
 
Mortality 
- There was no specific information on the degree of underreporting for each of the diseases 
- Some countries report mortality in general but specific causes are missing  
-> assumption of 0 deaths has been used 
- For some countries there are differences in the number of reported deaths between Eurostat 
and WHO  
 -> preference for Eurostat data in case of differences 
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4. Influenza 
 
Influenza is defined as an acute respiratory disease caused by influenza viruses (type A, B or 
C are recognized) which spreads via the respiratory route. Influenza is not only associated 
with increased general practice consultation rates, hospital admissions and excess deaths but 
also with increased days lost to absence (work or school).27  
 
4.1 Outcome tree 
 
The outcome tree for influenza is presented in Figure 4.1. In approximately 50% of the cases 
the infection is subclinical.28 Influenza symptoms are abrupt onset of fever and chills, 
accompanied by headache and sore throat, myalgia, malaise, anorexia and a dry cough.29 In 
uncomplicated influenza the fever usually lasts 2-5 days and healthy people recover within 1-
2 weeks without sequelae.30 According to Meier et al. 9.5% of the influenza cases in the 
United Kingdom between 1991-1996 had clinical complications (respiratory tract, heart, 
central nervous system, kidneys or other) within 30 days after diagnosis and 0.2% of the 
cases died within 30 days after diagnosis.31 Most common complications of influenza are 
secondary bacterial infections, especially otitis media and pneumonia.28 These complications 
were therefore included in the outcome tree. 
 
           
 
 
 
 
 
 
 
Figure 4.1 Outcome tree influenza (R=recovery) 
 
The influenza vaccine is effective in reducing illness, hospitalization and mortality, albeit 
effectiveness varies by target group and season.32, 33, 34 Annual vaccination of groups with 
high risk is the major strategy for controlling influenza infections.35, 36 The vaccination 
coverage among elderly in the European Union is known from only a limited number of 
countries and varies between 25% in Finland to 81% in the Netherlands, for other risk groups 
few data were available.37 Based on the number of doses of vaccine distributed in a country 
per 1,000 population, in 2000 vaccine use was lowest in Eastern Europe followed by the 
Scandinavian countries.38 
R
R 
Acute illness  
with fever Otitis media Deafness 
Pneumonia Death 
Infection 
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4.2 Baseline estimate of disease burden 
 
Specific data sources and assumptions regarding mortality, incidence, duration and severity 
of the different outcomes in the outcome tree of influenza are described in Appendix IV 
(Table IV.1 and IV.8). Based on this information the YLD, YLL and DALY for influenza 
have been calculated (Table 4.1). The disease burden for influenza is mainly dominated by 
mortality, and the burden due to complications (otitis media including deafness and 
pneumonia were taken into account) is considerably smaller than the burden due to the acute 
illness.  
 
Table 4.1 Morbidity, mortality and disease burden (DALYs per year) for influenza 
countries
incidence YLD 
acute
YLD 
compl.
YLD 
total
deaths      YLL DALY 
total
DALY per 
case
DALY  per 
100.000
Austria1 566 5.7 0.0 5.7 12 170.8 176.5 0.3 2.2
Belgium 874 8.7 0.0 8.8 - - - - -
Cyprus4 - - - - 0 0.0 - - -
Czech Republic 236 2.4 0.0 2.4 35 317.5 319.9 1.4 3.1
Denmark 117 1.2 0.0 1.2 - - - - -
Estonia - - - - 1 2.0 - - -
Finland - - - - 55 600.9 - - -
France3 2,650 26.5 0.1 26.6 475 4,631.7 4,658.3 1.8 7.5
Germany 1,372 13.7 0.1 13.8 212 2,147.7 2,161.5 1.6 2.6
Greece - - - - 0 0.0 - - -
Hungary - - - - 23 418.1 - - -
Ireland 179 1.8 0.0 1.8 7 114.8 116.6 0.7 2.9
Italy 621 6.2 0.0 6.2 - - - - -
Latvia 525 5.2 0.0 5.3 3 52.3 57.5 0.1 2.5
Lithuania 5 0.1 0.0 0.1 6 156.5 156.6 29.4 4.6
Luxembourg2 54 0.5 0.0 0.5 3 51.2 51.7 1.0 11.4
Malta - - - - 1 8.5 - - -
Netherlands 400 4.0 0.0 4.0 150 1,292.8 1,296.8 3.2 8.0
Poland 39 0.4 0.0 0.4 84 922.8 923.2 23.5 2.4
Portugal 400 4.0 0.0 4.0 11 80.0 84.0 0.2 0.8
Slovakia 200 2.0 0.0 2.0 - - - - -
Slovenia 146 1.5 0.0 1.5 3 16.5 18.0 0.1 0.9
Spain 570 5.7 0.0 5.7 135 925.7 931.4 1.6 2.2
Sweden1,3 1,667 16.7 0.1 16.7 79 630.9 647.7 0.4 7.2
United Kingdom 1,956 19.6 0.1 19.6 61 1,180.2 1,199.9 0.6 2.0
Iceland - - - - 2 10.5 - - -
Liechtenstein - - - - - - - - -
Norway 566 5.7 0.0 5.7 36 290.8 296.4 0.5 6.5
Note incidence = mean # of respiratory specimens tested positive for influenza 2002/2003-2004/2005 (data EISS)
mortality = mean # of deaths 2003-2004 (data Eurostat/WHO)
- = no data available
1 = incidence data 2004/2005 only
2 = incidence data 2003/2004 - 2004/2005 only
3 = mortality data 2003 only
4 = mortality data 2004 only
Morbidity Mortality DALY per year
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The disease burden is relatively high in the Scandinavian countries, the Netherlands, France 
and Luxembourg. In these countries the number of reported deaths due to influenza is 
relatively high. In the baseline estimate for disease burden the number of respiratory 
specimens tested positive for influenza reported to the European Influenza Surveillance 
Scheme (EISS) has been used as an estimate of the influenza incidence. However, usually the 
disease is self-limiting and diagnoses are generally not laboratory-confirmed. Therefore the 
true incidence of influenza is considerably higher than the reported incidence based on 
respiratory specimens tested positive for influenza. Table 4.1 also makes clear that based on 
laboratory data the incidence of influenza is substantially underestimated: in some countries 
(like for example Poland) the number of registered deaths due to influenza even exceeds the 
number of positive respiratory specimens.  
In the baseline scenario reported influenza mortality has been used to estimate YLL. 
However, research has shown that clinicians often attribute influenza-related deaths to a pre-
existing underlying condition (for example pneumonia) rather than to influenza.39 Therefore, 
it is difficult to identify true mortality due to influenza. Some other estimates for both 
incidence and mortality have been addressed in scenario analysis (section 4.3). 
 
4.3 Scenario analysis 
 
The incidence of influenza based on laboratory-confirmed data only (baseline scenario) is 
underestimated. Another indication that influenza morbidity was underestimated, is that the 
Public Health Status and Forecast studies estimated the Dutch morbidity for influenza in 
2003 on 5,454 YLD26 compared to 4 YLD in this pilot (Figure 4.2). In the Dutch study, the 
incidence of non-fatal cases was estimated from the number of general practitioner visits 
because of influenza-like-illness (corrected for the part of patients that will not seek medical 
attention but not corrected for the fact that not all influenza-like-illness can be ascribed to 
influenza). Figure 4.2 also shows the results of a scenario analysis for the Netherlands. 
Scenario 2 and 3 provide other morbidity estimates while scenario 4 provides another 
mortality estimate. 
 
In scenario 2 the mean number of general practitioner visits because of influenza-like-illness 
in the seasons 2003/2004 to 2005/200640 has been used as incidence estimate (n=260,655). 
This incidence has been corrected for the assumption that only 30% of the influenza patients 
in the Netherlands will visit their general practitioner24 and only 32,2% of the influenza-like-
illnesses in the Netherlands can be ascribed to influenza41 (based on laboratory confirmation 
for the influenza season 2005/2006). For the Netherlands the influenza incidence in this 
scenario was 279,770 cases per year (compared to 400 in the baseline scenario). This has a 
considerable impact on the morbidity estimate that changes from 4 YLD in the baseline 
scenario to 2,808 YLD in scenario 2.  
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In England and Wales approximately 800,000 GP consultations for respiratory illnesses each 
year are attributed to influenza,42 this incidence would result in 8,030 YLD compared to 20 
YLD for the United Kingdom in the baseline scenario. 
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Figure 4.2 Scenario analysis influenza for the Netherlands 
 
In scenario 3 the incidence was based on the assumption that the clinical attack rate of 
influenza during epidemics ranges from 10-20% in the general community.43 In this scenario 
the lowest estimate of 10% has been used because in half of the cases the infection is 
subclinical. For the Netherlands the influenza incidence in scenario 3 was 1,628,178 cases per 
year (compared to 279,770 in scenario 2), the YLD estimate changes to 16,342. For the 
Netherlands the incidence in scenario 3 seems to be too high because it is considerably higher 
when comparing to scenario 2 which is probably closest to reality (based on sentinel data). 
 
For the Netherlands Sprenger et al. estimated that in the period 1967-1989 the overall impact 
of influenza on mortality was greater than registered mortality by a factor of 3.6.44 In  
scenario 4 the registered mortality in all age classes was therefore multiplied by 3.6, which 
resulted in a mortality estimate of 4,654 (compared to 1,293 in the baseline scenario). The 
number of deaths could have been overestimated this way because the influenza virus seems 
to be less virulent in the last years41 and today vaccination coverage is considerably higher 
than in the period 1967-1989. Furthermore, YLL was probably overestimated because it is 
likely that people dying from influenza have un underlying disease and therefore a lower life 
expectancy. In the study of Sprenger et al. almost half of the non-registered influenza deaths 
were registered as deaths from heart disease, approximately 25% from lung disease and 
approximately 30% from other diseases.44 
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4.4 Discussion and recommendations 
 
Based on scenarios 2 (YLD) and 4 (YLL) combined, the Dutch disease burden of influenza 
may have been underestimated in the baseline scenario by a factor of at least five. It is likely 
that the burden was also underestimated for other countries. The number of respiratory 
specimens tested positive for influenza is not suitable as incidence indicator for disease 
burden calculations, because testing is not general practice (this applies for all the selected 
diseases but for influenza in particular). Future morbidity estimates need to concentrate on 
scenario 2. EISS collects data on general practitioner visits because of influenza-like-illness 
in different countries. Besides the wide range of national case definitions, estimated 
consultation rates may differ between countries due to differences in consultation behaviour, 
estimation procedure, vaccination coverage and obligatory doctor visits for absence from 
work or school.45, 46 The fraction of patients that visits their general practitioner and the 
proportion of influenza-like-illness that can be ascribed to influenza need to be determined 
for each of the countries.  
An alternative mortality estimate could be the excess all-cause mortality during periods of 
high circulation of influenza,39, 47 like the Dutch example in scenario 4. According to 
Armstrong et al. in people aged over 75 years the proportion of deaths attributable to 
influenza during periods of influenza for all cause mortality was 13,4% in unvaccinated 
people and 2.2% in vaccinated people.48 
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5. Measles 
 
Worldwide measles is still an important cause of death among children below five years old 
and measles is the leading cause of vaccine preventable deaths in children.28, 49 In many 
industrialized countries measles is now a rare disease but outbreaks still occur. Measles is one 
of the most contagious infectious diseases. The immunity degree of the population needed to 
prevent epidemic spread is very high, probably over 95%, which has not yet been achieved in 
all European countries. WHO aims to eliminate measles in the European region by 2010.50, 51 
According to the surveillance Community Network for Vaccine Preventable Infectious 
Diseases 82% of the reported measles cases with a known vaccination status occurred in 
unvaccinated children.52 Measles is caused by a respiratory virus (a morbillivirus) and 
spreads through direct contact.28 
 
5.1 Outcome tree 
 
The outcome tree for measles is shown in Figure 5.1. Measles starts with high fever, 
coughing, runny nose, red eyes and small white spots inside the cheeks (Koplik spots). After 
several days a red rash develops (usually on the face and upper neck).53, 50 Most important 
complications of measles are otitis media (5-10% of the cases), pneumonia (1-5% of the 
cases) and encephalitis (0.1% of the cases). A very rare complication is subacute sclerosing 
panencephalitis (SSPE), caused by persistent infection with measles virus, with nerves and 
brain tissue degeneration.28 In children who previously had natural measles the risk of 
developing SSPE is between 0.6 and 2.2 per 100,000 measles infections.54 
 
  
            
    
 
 
 
 
                
 
 
 
 
 
   
 
 
Figure 5.1 Outcome tree measles (R=recovery) 
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countries
incidence YLD 
acute
YLD 
compl.
YLD 
total
deaths      YLL DALY 
total
DALY per 
case
DALY  per 
100.000
Austria 41 0.2 0.3 0.5 4 187.3 187.9 4.6 2.3
Belgium 44 0.3 0.3 0.6 - - - - -
Cyprus3 0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0
Czech Republic 16 0.1 0.1 0.2 0 0.0 0.2 0.0 0.0
Denmark 1 0.0 0.0 0.0 - - - - -
Estonia 1 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0
Finland 0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0
France1,2 7,454 45.4 53.0 98.4 4 247.1 345.5 0.0 0.6
Germany 560 3.4 4.0 7.4 5 227.0 234.4 0.4 0.3
Greece 43 0.3 0.3 0.6 0 0.0 0.6 0.0 0.0
Hungary 1 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0
Ireland 333 2.0 2.4 4.4 1 30.9 35.3 0.1 0.9
Italy 4,293 26.2 30.5 56.7 - - - - -
Latvia 0 0.0 0.0 0.0 0 0.0 0.0 - 0.0
Lithuania 1 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0
Luxembourg 0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0
Malta 1 0.0 0.0 0.0 1 26.0 26.0 19.5 6.5
Netherlands 6 0.0 0.0 0.1 1 21.2 21.3 3.5 0.1
Poland 24 0.1 0.2 0.3 1 38.2 38.5 1.6 0.1
Portugal 5 0.0 0.0 0.1 4 227.5 227.6 42.7 2.2
Slovakia 1 0.0 0.0 0.0 - - - - -
Slovenia 0 0.0 0.0 0.0 0 0.0 0.0 - 0.0
Spain 98 0.6 0.7 1.3 3 115.8 117.1 1.2 0.3
Sweden2 7 0.0 0.0 0.1 0 0.0 0.1 0.0 0.0
United Kingdom 245 1.5 1.7 3.2 5 237.5 240.7 1.0 0.4
Iceland 0 0.0 0.0 0.0 0 0.0 0.0 - 0.0
Liechtenstein - - - - - - - - -
Norway 5 0.0 0.0 0.1 1 35.8 35.9 7.2 0.8
Note incidence = mean # of cases 2003-2005 (data Eurostat)
mortality = mean # of deaths 2003-2004 (data Eurostat/WHO)
- = no data available
1 = incidence data 2003-2004 only
2 = mortality data 2003 only
3 = mortality data 2004 only
Morbidity Mortality DALY per year
5.2 Baseline estimate of disease burden 
 
Specific data sources and assumptions regarding mortality, incidence, duration and severity 
of the different outcomes in the outcome tree of measles are described in Appendix IV 
(Table IV.2 and IV.8). Based on this information the YLD, YLL and DALY for measles have 
been calculated (Table 5.1). Except for countries with a relatively high number of measles 
cases and therefore morbidity (especially France and Italy), the disease burden for measles is 
mainly dominated by mortality. Unfortunately, Italy is one of the countries where mortality 
data were not generally available. In the countries Portugal, Malta, Norway, Austria and the 
Netherlands the number of reported deaths is relatively high compared to the number of 
reported measles cases, while the number of deaths in France seems to be relatively low.  
 
Table 5.1 Morbidity, mortality and disease burden (DALYs per year) for measles 
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The incidence of measles based on reported cases may be underestimated because many 
persons do not seek medical attention,55 however no alternative estimates were available. In 
scenario analysis the effect of an outbreak on the disease burden estimate have been studied 
(section 5.3). 
 
5.3 Scenario analysis 
 
There are considerable differences between disease burden estimates of the pilot baseline 
scenario and the Global Burden of Disease study (2002) (Figure 5.2). The differences 
between both estimates are mainly caused by differences in mortality and may be a random 
effect. Since measles mortality is rare, only one death more or less will have a considerable 
impact on disease burden (for example in the GBD estimate for the Netherlands the number 
of deaths in 2002 was 0, in the pilot there was 1 reported death in the period 2003-2004). 
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Figure 5.2 Comparison baseline scenario pilot for measles with Global Burden of Disease study  
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The difficulty with measles is that in most European countries there normally are very few 
cases and mortality is rare but there is always the risk of an outbreak situation which will lead 
to a sudden rise in incidence and therefore in disease burden. Scenario 2 provides another 
estimate for both morbidity and mortality (Figure 5.3). In this scenario the measles incidence 
and mortality data of a Dutch measles outbreak in 1999/2000 have been used. During this 
outbreak 3,292 measles cases and 3 deaths have been reported in the Netherlands56 which 
leads to a disease burden estimate of 258 DALYs per year. Although the disease burden for 
measles in scenario 2 is still low compared to other diseases, the effect of an outbreak is 
substantial (mainly due to mortality). However, if the mean incidence and mortality over a 
period including several years is considered, the effect of an outbreak will be smaller. 
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Figure 5.3 Scenario analysis measles for the Netherlands 
 
5.4 Discussion and recommendations 
 
The disease burden of measles is mainly dominated by mortality even though a number of 
complications (otitis media including deafness, pneumonia, encephalitis including sequelae 
and SSPE) were taken into account. Morbidity could have been underestimated due to 
underreporting of the “acute phase”. Studies in England/Wales and the USA have shown that 
the notification efficiency for measles rarely exceeds 40%, even in outbreak situations.57, 58 
However, even in the outbreak situation of scenario 2 the morbidity burden is just 17% of the 
total disease burden. The case-fatality ratio differs substantially between countries. There is 
no information on the degree of underreporting; in particular better data on measles-related 
mortality are important for disease burden estimates. In general the disease burden of measles 
is relatively low compared to other diseases but the effect of an outbreak is substantial. This 
demonstrates the importance of prevention efforts.  
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6. HIV-infection 
 
There are indications that sexually transmitted infections are again on the rise in many 
countries in the European Union.59 HIV-infection, caused by the Human Immunodeficiency 
Virus through contact with infected body fluids (sexual contact, blood, pre/perinatal or 
breast-feeding), is spread worldwide. At the end of 2005 an estimated 38.6 million 
(33.4 million – 46.0 million) people worldwide were living with HIV.60 Rates of new HIV 
diagnoses vary greatly between countries in Europe. In general, the total number of reported 
HIV cases in Western and Central Europe is low compared to Eastern Europe.22 In Eastern 
Europe a considerable number of new HIV-infections is acquired through intravenous drug 
use.61  
 
6.1 Outcome tree 
 
In Figure 6.1 the outcome tree for HIV-infection is shown. Primary infection with HIV can 
be accompanied by influenza-like symptoms for some days to weeks, which occurs in more 
than half of the cases. The diagnosis HIV is rarely made at this stage. The primary infection 
is followed by an asymptomatic period.62 Without treatment, HIV-infection almost always 
leads to progressive immunosuppression (symptomatic infection) that can lead to Acquired 
Immunodeficiency Syndrome (AIDS) and death. Well known examples of opportunistic 
infection and malignancy related to AIDS are pneumonia caused by Pneumocystis carinii and 
Kaposi’s sarcoma (cancer of connective tissue).28 Tuberculosis is the most frequently 
diagnosed AIDS indicative disease.22  
 
 
 
 
 
Figure 6.1 Outcome tree HIV-infection 
 
Highly Active Anti-Retroviral Therapy (HAART), standard of care from 1996 onwards, can 
delay symptomatic infection and the onset of AIDS with years. Before the introduction of 
HAART most HIV-infected people progress to AIDS within 10 years of infection and to 
death in less than 2 years after AIDS diagnosis. As a result of the widespread use of HAART, 
the incidence of AIDS cases and AIDS related deaths in Europe have strongly  
declined.63, 64, 65, 66 Possible complications of (long-term) usage of HAART are toxicities, 
metabolic changes and immune reconstitution disease.61 In all countries of the European 
Union the access to HAART in 2005 is good (=over 75%). However in 2003 the access to 
HAART in Estonia, Latvia and Lithuania was only partial (10-70%).67 
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countries
incidence 
HIV 
incidence 
AIDS 
YLD 
HIV
YLD 
AIDS
YLD 
total
deaths      YLL DALY 
total
DALY per 
case
DALY  per 
100.000
Austria 449 88 605.0 89.0 693.9 52 1,879.1 2,573.1 5.7 31.5
Belgium 1,038 168 1,411.3 169.8 1,581.1 - - - - -
Cyprus1,7 31 - 29.2 - - 1 16.6 - - -
Czech Republic 76 11 72.1 5.6 77.7 0 0.0 77.7 1.0 0.8
Denmark 284 48 386.3 48.2 434.5 - - - - -
Estonia 735 23 699.4 11.3 710.7 14 704.7 1,415.4 1.9 104.9
Finland 133 23 180.3 23.2 203.6 8 297.0 500.6 3.8 9.6
France2,6 5,493 1,463 7,474.1 1,478.8 8,952.9 1,044 37,043.1 45,996.0 8.4 74.0
Germany 2,200 1,058 2,992.8 1,069.1 4,061.9 505 17,335.3 21,397.2 9.7 25.9
Greece 485 101 660.3 102.1 762.4 18 651.1 1,413.5 2.9 12.8
Hungary 81 28 77.5 13.9 91.4 10 323.7 415.1 5.1 4.1
Ireland 358 48 486.3 48.9 535.1 15 638.3 1,173.4 3.3 28.8
Italy3 1,094 1,651 1,486.8 1,669.2 3,156.0 - - - - -
Latvia 342 75 325.5 37.8 363.3 14 568.5 931.8 2.7 40.3
Lithuania 122 13 116.0 6.7 122.7 7 261.4 384.2 3.2 11.2
Luxembourg 57 9 77.1 9.4 86.6 4 108.2 194.8 3.4 43.0
Malta4 18 2 17.2 1.0 18.2 2 47.7 65.8 3.7 16.4
Netherlands 1,361 243 1,849.7 245.6 2,095.3 86 2,956.6 5,051.9 3.7 31.0
Poland 639 162 608.5 80.9 689.4 122 5,194.9 5,884.3 9.2 15.4
Portugal 2,561 989 3,486.3 999.3 4,485.6 940 36,223.8 40,709.5 15.9 387.6
Slovakia 16 3 15.6 1.3 16.9 - - - - -
Slovenia 25 9 23.8 4.4 28.2 2 61.3 89.5 3.6 4.5
Spain - 2,383 - 2,408.4 - 1,592 60,467.6 - - -
Sweden6 395 60 536.8 60.6 597.5 29 870.0 1,467.5 3.7 16.3
United Kingdom 7,757 898 10,549.5 907.7 11,457.2 228 8,652.8 20,109.9 2.6 33.6
Iceland 8 2 10.4 1.7 12.1 1 16.6 28.7 3.7 9.8
Liechtenstein - - - - - - - - - -
Norway5 225 39 306.1 39.4 345.5 20 623.1 968.6 4.3 21.1
Note incidence = mean # of cases 2003-2005 (data EuroHIV)
mortality = mean # of deaths 2003-2004 (data Eurostat/WHO)
DALY per case = DALY per HIV-case
- = no data available
1 = 40% HIV-cases were non-residents
2 = incidence data HIV 2004 only, AIDS 2003-2004 only
3 = incidence data HIV for seven regions only
4 = incidence data HIV 2004-2005 only
5 = incidence data HIV and AIDS 2003 only
6 = mortality data 2003 only
7 = mortality data 2004 only
Morbidity Mortality DALY per year
6.2 Baseline estimate of disease burden 
 
Specific data sources and assumptions regarding mortality, incidence, duration and severity 
of the different outcomes in the outcome tree of HIV-infection are described in Appendix IV 
(Table IV.3 and IV.8). Based on this information the YLD, YLL and DALY for HIV have 
been calculated (Table 6.1). HIV-infection is one of the diseases for which both morbidity 
and mortality have a substantial impact on the disease burden. The disease burden of HIV-
infection is relatively high in Portugal, Estonia, France and probably Italy and Spain.  
 
Table 6.1 Morbidity, mortality and disease burden (DALYs per year) for HIV-infection 
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Unfortunately, the disease burden in Italy and Spain could not be fully calculated because 
these countries have not yet implemented HIV case reporting at national level.22 The disease 
burden per case is remarkably high in Portugal because the number of deaths is relatively 
high compared with other countries. Possibly, this can be explained by underreporting of new 
HIV-infections in Portugal. 
 
ECDC states that the HIV-epidemic in Europe is not one but a multitude of diverse epidemics 
because the epidemic exhibits very different patterns in the different countries in terms of 
magnitude, trends and affected populations.68 HIV-infection will lead to AIDS so the 
difference in the number of HIV- and AIDS-cases in Table 6.1 is noticeable: the AIDS 
incidence and number of deaths is much lower than the HIV-incidence (except for Italy but in 
this country the HIV-incidence is based on seven regions only). Most likely this is an effect 
of the introduction of HAART, by which the onset of AIDS and death is delayed.  
The incidence of HIV-infection is difficult to determine because in many cases the diagnosis 
is not made in an early stage. Furthermore, the incidence data of EuroHIV were based on the 
year of reporting and not on the year of diagnosis. Finally, it must be noted that for AIDS this 
is not a true incidence approach because the new cases of AIDS in 2003-2005 are the result 
of older HIV-infections (not the result from HIV-infections in 2003-2005). However no 
alternative incidence estimates were available. Also, duration and severity weights of HIV/ 
AIDS used in the baseline estimate have been derived before the widespread use of HAART. 
In scenario analysis the effect of new estimates for duration and severity of HIV-infection, 
which take HAART into account, have been studied. Furthermore, a scenario has been 
calculated in which all new HIV-cases develop AIDS and die due to HIV (section 6.3). 
 
6.3 Scenario analysis 
 
For most countries the estimates of the pilot baseline scenario and the Global Burden of 
Disease study (2002) are in the same order of magnitude (Figure 6.2). For HIV-infection in 
the Netherlands the differences between the pilot study and more extensive studies as the 
Public Health Status and Forecast studies and the Global Burden of Disease study are not 
substantial (Figure 6.3). It must be noted however that in the Dutch Public Health Status and 
Forecast studies only AIDS has been taken into account.  
Figure 6.3 also shows the results of a scenario analysis for the Netherlands. In the baseline 
scenario the implemented duration and severity weights for HIV and AIDS have been derived 
before the widespread use of HAART. In scenario 2 the same incidence and mortality data 
were included but new estimates for the duration and severity of HIV and AIDS were applied 
(based on person perceived health related quality of life; Table 6.2).69 The morbidity estimate 
in scenario 2 is higher than in the baseline scenario, mainly due to the longer duration of the 
disease (see also Figure 6.4 for other countries). 
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Figure 6.2   Comparison baseline scenario pilot for HIV with Global Burden of Disease study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 Scenario analysis HIV-infection for the Netherlands 
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Table 6.2 Duration and severity weights for HIV and AIDS in the different scenarios 
 HIV  AIDS 
scenario duration severity  duration severity 
baseline scenario 
(prior to HAART)23, 17 
10 year (EME) 
  7 year (FSE + MEC) 
0.123 (00-14 year)  
0.136 (15+ year) 
 2 year (EME) 
1 year (FSE + MEC) 
0.505 
scenario 2/3 
(HAART taken into account)69  
17.20 year 0.20  5.36 year 0.38 
 
 
694
1,581
78
434
711
204
8,953
4,062
762
91
535
3,156
363
123
87
18
2,095
689
4,486
17
28
597
11,457
12
345
1,726
3,921
283
1,076
2,578
504
21,915
9,737
1,879
337
1,331
7,134
1,331
447
214
66
5,185
2,533
10,843
62
104
1,485
28,566
30
855
0 5,000 10,000 15,000 20,000 25,000 30,000
Austria
Belgium
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Ireland
Italy
Latvia
Lithuania
Luxembourg
Malta
Netherlands
Poland
Portugal
Slovakia
Slovenia
Sweden
United Kingdom
Iceland
Norway
Morbidity (YLD per year)
pilot baseline scenario (YLD) scenario 2 (YLD)  
Figure 6.4 Comparison morbidity (YLD) baseline scenario pilot for HIV-infection with scenario 2 
 
In scenario 3, the new estimates for duration and severity from Herida et al. were applied too, 
but reported incidence of AIDS and reported mortality was replaced by the assumption that 
every HIV-infected person lives 22.57 years (17.20 years with HIV and 5.36 years with 
AIDS69) and subsequently dies due to HIV/AIDS. In this scenario the disease burden is much 
higher (Figure 6.3) because the incidence of AIDS and mortality is estimated much higher 
(n=1,361) than the reported incidence of AIDS (n=243) and mortality (n=86) in the baseline 
scenario.  
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It must be noted that in scenario 3 mortality was overestimated because not all HIV-infected 
persons will die because of HIV/AIDS and with increasing survival, a growing part of 
patients with HIV/AIDS will die due to other causes. Among HIV-patients in the Netherlands 
the proportion of HIV-related causes of death declined from 76% in 1996 to 39% in 2005.70 
Scenario 4, in which we included only 39% of the years of life lost from scenario 3, seems to 
be more realistic even though we do not know if death due to other causes is spread evenly 
over different age categories. 
 
6.4 Discussion and recommendations 
 
Seeing the considerable differences between the scenarios we need to have better insight in 
the course of the disease, especially because there are remarkable differences in the ratio of 
HIV-cases, AIDS-cases and deaths between countries. Because of the long duration of the 
disease it does not seem right to combine incidence and mortality data from the same 
calendar years, especially because of the enormous effect of HAART. Furthermore, not all 
HIV-infected people will develop AIDS and die due to HIV-infection. Advanced 
mathematical modelling of the HIV epidemic is required to provide a better basis for disease 
burden estimation. 
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7. Campylobacteriosis 
 
The most frequently reported zoonotic disease in humans in the European Union in 2004 is 
Campylobacteriosis, caused by thermophilic Campylobacter spp. Campylobacteriosis is often 
acquired through contaminated food or water.71, 28 For unknown reasons, the incidence of 
Campylobacter infections in developed countries has been increasing for several years.72 
Although an overall decreasing trend has been observed in Europe in the period from 2001-
2003, in 2004 the number of cases increased again.71 
 
7.1 Outcome tree  
 
The outcome tree for campylobacteriosis9 is presented in Figure 7.1. Campylobacter 
infections may cause acute gastroenteritis (in most cases self-limiting within a few days to 
weeks). The disease may be fatal for few patients and may result in complications, of which 
Guillain-Barré syndrome (GBS), reactive arthritis (ReA) and inflammatory bowel disease 
(IBD) are the most significant.9 
 
        
 
 
 
      
 
 
   
 
 
 
 
Figure 7.1 Outcome tree Campylobacter–associated gastroenteritis and sequelae (R=recovery)9 
 
 
7.2 Baseline estimate of disease burden 
 
Specific data sources and assumptions regarding mortality, incidence, duration and severity 
of the different outcomes in the outcome tree of campylobacteriosis are described in 
Appendix IV (Table IV.4 and IV.8). Based on this information the YLD, YLL and DALY for 
campylobacteriosis have been calculated (Table 7.1). The disease burden of 
campylobacteriosis is mainly dominated by morbidity, mortality is rarely reported. Especially 
in the Czech Republic, the disease burden due to campylobacteriosis is relatively high. There 
is no information on the degree of underreporting of campylobacteriosis. In scenario analysis 
two other incidence estimates have been taken into account (section 7.3). 
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Table 7.1 Morbidity, mortality and disease burden (DALYs per year) for campylobacteriosis 
countries
incidence YLD 
acute
YLD 
compl.
YLD 
total
deaths      YLL DALY 
total
DALY per 
case
DALY  per 
100.000
Austria 4,743 50.5 478.4 528.9 0 0.0 528.9 0.1 6.5
Belgium1 6,474 69.0 653.0 721.9 - - - - -
Cyprus2,6 0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0
Czech Republic 25,274 269.3 2,549.1 2,818.4 0 0.0 2,818.4 0.1 27.6
Denmark 3,646 38.8 367.7 406.5 - - - - -
Estonia 115 1.2 11.6 12.9 0 0.0 12.9 0.1 1.0
Finland 3,588 38.2 361.9 400.1 0 0.0 400.1 0.1 7.7
France3,5 1,997 21.3 201.4 222.7 0 0.0 222.7 0.1 0.4
Germany 55,253 588.7 5,572.8 6,161.5 1 3.6 6,165.1 0.1 7.5
Greece - - - - 0 0.0 - - -
Hungary 8,551 91.1 862.4 953.5 0 0.0 953.5 0.1 9.4
Ireland 1,694 18.0 170.9 188.9 0 0.0 188.9 0.1 4.6
Italy 3 0.0 0.3 0.3 - - - - -
Latvia 0 0.0 0.0 0.0 0 0.0 0.0 0.1 0.0
Lithuania 703 7.5 70.9 78.4 0 0.0 78.4 0.1 2.3
Luxembourg - - - - 0 0.0 - - -
Malta 92 1.0 9.3 10.3 0 0.0 10.3 0.1 2.6
Netherlands3 2,205 23.5 222.4 245.9 1 18.9 264.7 0.1 1.6
Poland4 36 0.4 3.6 4.0 0 0.0 4.0 0.1 0.0
Portugal - - - - 0 0.0 - - -
Slovakia 1,697 18.1 171.1 189.2 - - - - -
Slovenia 1,014 10.8 102.2 113.0 0 0.0 113.0 0.1 5.7
Spain 5,854 62.4 590.4 652.8 0 0.0 652.8 0.1 1.5
Sweden5 6,723 71.6 678.1 749.7 0 0.0 749.7 0.1 8.3
United Kingdom 50,834 541.6 5,127.0 5,668.6 3 20.6 5,689.3 0.1 9.5
Iceland 127 1.4 12.8 14.2 0 0.0 14.2 0.1 4.9
Liechtenstein - - - - - - - - -
Norway 2,393 25.5 241.4 266.9 0 0.0 266.9 0.1 5.8
Note incidence = mean # of cases 2003-2005 (data Eurostat)
mortality = mean # of deaths 2003-2004 (data Eurostat/WHO)
- = no data available
1 = incidence data 2003-2004 only
2 = incidence data 2005 only
3 = incidence data 2003 only
4 = incidence data 2004-2005 only
5 = mortality data 2003 only
6 = mortality data 2004 only
Morbidity Mortality DALY per year
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7.3 Scenario analysis 
 
Comparing the results of the pilot with more extensive studies at the RIVM,9 it becomes clear 
that in these studies the disease burden estimate is almost a factor five higher than in the pilot 
(Figure 7.2). The higher mortality can be explained by the fact that in these more extensive 
studies mortality estimates were based on Danish cohort studies,73 instead of on reported 
deaths (pilot). The morbidity in more extensive studies was based on data of the RIVM. 
According to these RIVM data the number of new campylobacteriosis cases in 2003 in the 
Netherlands was n=5,387 (corrected for the coverage of the system). The absolute number of 
reported cases to the sentinel laboratories was 2,805. According to Eurostat the number of 
cases in 2003 (2004-2005 not available) was n=2,205 instead of 2,805.  
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Figure 7.2 Scenario analysis campylobacteriosis for the Netherlands  
 
Figure 7.2 also shows the results of a scenario analysis for the Netherlands. In scenario 2 the 
morbidity estimate (YLD) was based on RIVM data (mean incidence 2003-2005 n=6,241), 
which is more in line with more extensive studies of the RIVM. It is not clear why the Dutch 
data of RIVM and Eurostat are not identical and why recent data are lacking, but possibly this 
is also the case for other countries. 
 
In scenario 3 the morbidity estimate is based on the incidence of campylobacteriosis derived 
from a study among Swedish travellers. In this study returning tourists were used as a sentinel 
population to identify the risk of campylobacteriosis. The estimated risk for the Netherlands 
was 9.1 per 100,000 travellers.74 Applied to the average Dutch population of 2004 this results 
in an YLD estimate of 165. For the Netherlands this scenario does not seem very realistic 
compared to scenario 2 and more extensive studies in which morbidity is higher.  
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In Figure 7.3 the comparison for the baseline scenario and scenario 3 for other countries is 
shown. For some countries the morbidity (YLD) in scenario 3 is higher than in the baseline 
estimate but for other countries it is just the other way around. 
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Figure 7.3 Comparison morbidity (YLD) baseline scenario pilot for campylobacteriosis with 
scenario 3 
7.4 Discussion and recommendations 
 
Based on scenario 2 and the more extensive studies of the RIVM, the disease burden of 
campylobacteriosis in the baseline estimate of this pilot was underestimated. Differences 
between national and Eurostat incidence data need to be sorted out and and Eurostat needs to 
take into account the coverage of the sentinel systems from which the data are derived. Data 
from Enter-net may be appropriate to include in the future, this needs to be investigated. 
Scenario 3 gives the idea that there are perhaps considerable differences between countries in 
the degree of underreporting which needs to be investigated. Furthermore, future estimates of 
disease burden of campylobacteriosis should include other mortality data than reported 
mortality. 
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8. EHEC-infection 
 
While less frequently reported than Campylobacter and Salmonella infections, E. coli 
infection is one of the most severe zoonotic illnesses due to high morbidity and mortality in 
vulnerable populations and children.71 Enterohaemorrhagic Escherichia coli (EHEC) 
produces toxins, known as verotoxins (or Shiga-like toxins because of their similarity to the 
toxins produced by Shigella dysenteriae). EHEC is primarily transmitted through 
consumption of contaminated food28, 75 although increasingly direct animal contact and 
environmental transmission are reported. 
 
8.1 Outcome tree 
 
In Figure 8.1 the outcome tree for enterohaemorrhagic Escherichia coli9 is shown. Mild and 
self-limiting gastroenteritis can occur after infection but particularly among children under 
five years of age there is also a probability of developing haemolytic-uraemic syndrome 
(HUS) which can result in end-stage renal disease (ESRD).9 
 
                   
 
 
 
 
 
 
 
           
 
 
 
 
 
Figure 8.1 Outcome tree for infection with enterohaemorrhagic Escherichia coli 
 (R=recovery)9 
 
8.2 Baseline estimate of disease burden 
 
Specific data sources and assumptions regarding mortality, incidence, duration and severity 
of the different outcomes in the outcome tree of EHEC-infection are described in  
Appendix IV (Table IV.5 and IV.8). Based on this information the YLD, YLL and DALY for 
EHEC-infection have been calculated (Table 8.1). Just like campylobacteriosis, the disease 
burden of EHEC-infection is mainly dominated by morbidity, mortality is seldom reported. 
Again, in the Czech Republic, the disease burden is relatively high. There is no information 
on the degree of underreporting. 
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Table 8.1 Morbidity, mortality and disease burden (DALYs per year) for EHEC-infection 
countries
incidence YLD 
acute
YLD 
compl.
YLD 
total
deaths      YLL DALY 
total
DALY per 
case
DALY  per 
100.000
Austria 17 0.1 9.1 9.2 1 3.6 12.8 0.7 0.2
Belgium - - - - - - - - -
Cyprus1,3 0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0
Czech Republic 1,678 10.1 877.8 888.0 0 0.0 888.0 0.5 8.7
Denmark 142 0.9 74.1 75.0 - - - - -
Estonia 35 0.2 18.5 18.7 0 0.0 18.7 0.5 1.4
Finland 15 0.1 8.0 8.1 1 30.9 39.0 2.5 0.7
France2 - - - - 0 0.0 - - -
Germany 5,647 34.0 2,953.8 2,987.8 0 0.0 2,987.8 0.5 3.6
Greece 1 0.0 0.7 0.7 0 0.0 0.7 0.5 0.0
Hungary 184 1.1 96.4 97.5 0 0.0 97.5 0.5 1.0
Ireland 89 0.5 46.4 46.9 0 0.0 46.9 0.5 1.2
Italy - - - - - - - - -
Latvia 15 0.1 7.8 7.9 0 0.0 7.9 0.5 0.3
Lithuania 150 0.9 78.3 79.2 0 0.0 79.2 0.5 2.3
Luxembourg - - - - 0 0.0 - - -
Malta 10 0.1 5.2 5.3 0 0.0 5.3 0.5 1.3
Netherlands 55 0.3 28.8 29.1 0 0.0 29.1 0.5 0.2
Poland1 1,430 8.6 747.9 756.6 0 0.0 756.6 0.5 2.0
Portugal - - - - 0 0.0 - - -
Slovakia 561 3.4 293.4 296.8 - - - - -
Slovenia 146 0.9 76.5 77.4 0 0.0 77.4 0.5 3.9
Spain 1,007 6.1 526.9 532.9 0 0.0 532.9 0.5 1.2
Sweden2 220 1.3 114.9 116.2 0 0.0 116.2 0.5 1.3
United Kingdom 995 6.0 520.4 526.4 0 0.0 526.4 0.5 0.9
Iceland 3 0.0 1.4 1.4 0 0.0 1.4 0.5 0.5
Liechtenstein - - - - - - - - -
Norway 31 0.2 16.4 16.6 0 0.0 16.6 0.5 0.4
Note incidence = mean # of cases 2003-2005 (data Eurostat)
mortality = mean # of deaths 2003-2004 (data Eurostat/WHO)
- = no data available
1 = incidence data 2005 only
2 = mortality data 2003 only
3 = mortality data 2004 only
Morbidity Mortality DALY per year
 
 
8.3 Scenario analysis 
 
When comparing the results of the pilot for EHEC-infection with more extensive studies of 
the RIVM,9 it becomes clear that in the latter studies the disease burden estimate is over three 
times higher than in the pilot due to a higher mortality (Figure 8.2). This can be explained by 
the fact that in these more extensive studies mortality due to HUS and end-stage renal disease 
(ESRD) were taken into account. 
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Figure 8.2 Comparison baseline scenario pilot for EHEC-infection with more extensive studies for 
the Netherlands 
 
8.4 Discussion and recommendations 
 
The disease burden of EHEC-infection in the baseline estimate of this pilot was 
underestimated. Future estimates of disease burden of EHEC-infection should include other 
mortality data than reported mortality. Data from Enter-net may be appropriate to include in 
the future, this needs to be investigated. 
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9. Salmonellosis 
 
The second most frequently reported zoonotic disease in humans in the European Union in 
2004 is Salmonella infection. The overall reported incidence of salmonellosis is slightly 
lower than of campylobacteriosis.71 Salmonellosis is caused by bacteria of the genus 
Salmonella (in particular S. Enteritidis and S. Typhimurium) and is generally contracted 
through the consumption of contaminated food of animal origin.76 
 
9.1 Outcome tree 
 
The outcome tree for salmonellosis9 is presented in Figure 9.1. Salmonella infections may 
cause acute gastroenteritis (in most cases self-limiting within a few days to weeks). The 
disease may be fatal for few patients and may result in complications, of which reactive 
arthritis (ReA) and inflammatory bowel disease (IBD) are the most significant. Sepsis is a 
rare complication and was therefore not taken into account.9 
 
           
 
 
 
 
 
 
      
   
 
 
Figure 9.1 Outcome tree Salmonella–associated GE and sequelae (R=recovery)9 
 
9.2 Baseline estimate of disease burden 
 
Specific data sources and assumptions regarding mortality, incidence, duration and severity 
of the different outcomes in the outcome tree of salmonellosis are described in Appendix IV 
(Table IV.6 and IV.8). Based on this information the YLD, YLL and DALY for 
salmonellosis have been calculated (Table 9.1). The disease burden for samonellosis is 
mainly dominated by morbidity but reported mortality is less rare than for campylobacteriosis 
and EHEC-infection. Again, the disease burden is relatively high in the Czech Republic 
followed by Slovenia. There is no information on the degree of underreporting of 
salmonellosis. In scenario analysis two other incidence estimates have been taken into 
account (section 9.3). 
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Table 9.1 Morbidity, mortality and disease burden (DALYs per year) for salmonellosis 
countries
incidence YLD 
acute
YLD 
compl.
YLD 
total
deaths      YLL DALY 
total
DALY per 
case
DALY  per 
100.000
Austria 6,486 78.4 336.3 414.7 3 38.2 452.9 0.1 5.5
Belgium1 11,219 135.6 581.7 717.3 - - - - -
Cyprus4 74 0.9 3.8 4.7 0 0.0 4.7 0.1 0.6
Czech Republic 30,183 364.8 1,565.2 1,930.0 1 16.7 1,946.7 0.1 19.1
Denmark 1,675 20.2 86.9 107.1 - - - - -
Estonia 210 2.5 10.9 13.4 0 0.0 13.4 0.1 1.0
Finland 2,335 28.2 121.1 149.3 1 2.0 151.3 0.1 2.9
France1,3 8,319 100.5 431.4 531.9 15 152.7 684.6 0.1 1.1
Germany 57,419 694.0 2,977.5 3,671.5 54 577.2 4,248.7 0.1 5.1
Greece 1,290 15.6 66.9 82.5 1 18.9 101.3 0.1 0.9
Hungary 8,390 101.4 435.1 536.5 5 77.1 613.6 0.1 6.1
Ireland 404 4.9 21.0 25.9 0 0.0 25.9 0.1 0.6
Italy 9,756 117.9 505.9 623.8 - - - - -
Latvia 645 7.8 33.4 41.2 1 18.9 60.1 0.1 2.6
Lithuania 1,804 21.8 93.5 115.4 0 0.0 115.4 0.1 3.4
Luxembourg 319 3.9 16.5 20.4 1 2.0 22.4 0.1 4.9
Malta 116 1.4 6.0 7.4 0 0.0 7.4 0.1 1.8
Netherlands2 2,012 24.3 104.3 128.7 9 120.6 249.2 0.1 1.5
Poland 16,107 194.7 835.3 1,029.9 8 112.1 1,142.0 0.1 3.0
Portugal 553 6.7 28.7 35.4 1 11.5 46.8 0.1 0.4
Slovakia 12,936 156.3 670.8 827.1 - - - - -
Slovenia 2,904 35.1 150.6 185.7 1 8.3 194.0 0.1 9.7
Spain 7,373 89.1 382.3 471.4 23 291.5 763.0 0.1 1.8
Sweden3 3,609 43.6 187.1 230.7 1 24.5 255.2 0.1 2.8
United Kingdom 14,588 176.3 756.5 932.8 14 231.2 1,163.9 0.1 1.9
Iceland 112 1.3 5.8 7.1 1 3.6 10.7 0.1 3.7
Liechtenstein - - - - - - - - -
Norway 1,529 18.5 79.3 97.7 1 13.2 111.0 0.1 2.4
Note incidence = mean # of cases 2003-2005 (data Eurostat)
mortality = mean # of deaths 2003-2004 (data Eurostat/WHO)
- = no data available
1 = incidence data 2003-2004 only
2 = incidence data 2003 only
3 = mortality data 2003 only
4 = mortality data 2004 only
Morbidity Mortality DALY per year
 
 
9.3 Scenario analysis 
 
Comparing the results of the pilot with more extensive studies at the RIVM,9 it becomes clear 
that in these studies the disease burden estimate is more than two and a half times higher than 
in the pilot (Figure 9.2). The higher mortality can be explained by the fact that in these more 
extensive studies mortality estimates were based on Danish cohort studies,73 instead of on 
reported deaths (pilot). The morbidity in more extensive studies was based on data of the 
RIVM. According to this RIVM data the number of new salmonellosis cases in 2003 in the 
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Netherlands was n= 3,359 (corrected for the coverage of the system). The absolute number of 
reported cases to the sentinel laboratories was 2,142. According to Eurostat the number of 
cases in 2003 (2004-2005 not available) was n= 2,012 instead of 2,142. 
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Figure 9.2 Scenario analysis salmonellosis for the Netherlands 
 
Figure 9.2 also shows the results of a scenario analysis for the Netherlands. In scenario 2 the 
morbidity estimate (YLD) was based on RIVM data (mean incidence 2003-2005 n= 2,695), 
which is more in line with more extensive studies of the RIVM. It is not clear why the Dutch 
data of RIVM and Eurostat for salmonellosis are not identical and why recent data are 
lacking, but possibly this is also the case for other countries. 
In scenario 3 the morbidity estimate is based on the incidence of salmonellosis derived from a 
study among Swedish travellers. In this study returning tourists were used as a sentinel 
population to identify the risk of salmonellosis. The estimated risk for the Netherlands was 98 
per 100,000 travellers.77 Applied to the average Dutch population of 2004 this results in an 
YLD estimate of 1,020. For the Netherlands this scenario does not seem very realistic 
compared to scenario 2 and more extensive studies in which morbidity is lower. In Figure 9.3 
the comparison for the baseline scenario and scenario 3 for other countries is shown. In most 
countries the morbidity (YLD) in scenario 3 is considerably higher than in the baseline 
estimate. 
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9.4 Discussion and recommendations 
 
Based on scenario 2 and the more extensive studies of the RIVM, the disease burden of 
salmonellosis in the baseline estimate of this pilot was underestimated. Differences between 
national and Eurostat incidence data need to be sorted out and Eurostat needs to take into 
account the coverage of the sentinel systems from which the data are derived. Data from 
Enter-net may be appropriate to include in the future, this needs to be investigated. Scenario 3 
gives the idea that there are perhaps considerable differences between countries in the degree 
of underreporting which needs to be investigated. Furthermore, future estimates of disease 
burden of salmonellosis should include other mortality data than reported mortality. 
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Figure 9.3 Comparison morbidity (YLD) baseline scenario pilot for salmonellosis with scenario 3 
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10. Tuberculosis 
 
Tuberculosis is defined as an infection with bacteria of the Mycobacterium tuberculosis-
complex and the infection spreads through the air.28 In 2004 there were nine million new 
tuberculosis cases reported worldwide and approximately two million tuberculosis deaths. 
More than 80% of all identified tuberculosis patients live in sub-Saharan Africa and Asia.78 
In the European Union tuberculosis morbidity is concentrated in vulnerable groups 
(populations of foreign origin, elderly people, HIV infected patients).79, 80 The incidence (per 
100.00) is highest in the Baltic States (Estonia, Latvia and Lithuania) and Portugal.81  
 
10.1 Outcome tree 
 
In Figure 10.1 the outcome tree for tuberculosis is shown. The infection usually gives no 
symptoms. Approximately 10-15% of the infected persons is expected to develop active 
tuberculosis (pulmonary or extrapulmonary) during life, the majority within the first two 
years. The remainder may develop a latent infection. Reduced immunity, including ageing, 
can induce reactivation of a latent infection. Coughing, fatigue, fever, losing weight and night 
sweating are the most important symptoms of pulmonary tuberculosis. Without treatment 
tuberculosis will lead to premature death. Treatment of tuberculosis consists of long-term 
multiple drug medication (at least six months).28, 82 Extrapulmonary tuberculosis occurs less 
frequently (30%) than pulmonary tuberculosis (70%).43 Treatment failures can result in the 
emergence of multidrug-resistant tuberculosis (MDR-TB). In case of infection with MDR-
TB, the duration of treatment can rise to two years and consists of a complicated combination 
of antibiotics, chemotherapeutics and incidentally surgery.83, 82 Treatment and prognosis of 
these patients resemble malignancy more than infection. So far, MDR-TB is mainly confined 
to eastern European populations, but may spread in the near future. The emergence of 
extremely resistant TB strains (XDR-TB) threatens to increase the potential burden of 
infection substantially. So far, the incidence of XDR-TB in Europe is relatively low.84 
Because MDR-TB is an important problem which needs specific attention, it is included in 
the outcome tree. However, MDR-TB is more a specific form of tuberculosis rather than a 
true separate outcome (therefore a dotted line is used in the outcome tree).  
  
 
 
             
 
 
 
       
          
Figure 10.1 Outcome tree tuberculosis (R=recovery, MDR-TB = multidrug-resistant tuberculosis) 
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10.2 Baseline estimate of disease burden 
 
Specific data sources and assumptions regarding mortality, incidence, duration and severity 
of the different outcomes in the outcome tree of tuberculosis are described in Appendix IV 
(Table IV.7 and IV.8). Based on this information the YLD, YLL and DALY for tuberculosis 
have been calculated (Table 10.1). The disease burden of tuberculosis is mainly dominated by 
mortality. The disease burden is relatively high in the Baltic States (Lithuania, Latvia and 
Estonia), Hungary, Portugal and Poland. 
 
Table 10.1 Morbidity, mortality and disease burden (DALYs per year) for tuberculosis 
countries
incidence YLD 
acute
YLD 
compl.
YLD 
total
deaths      YLL DALY 
total
DALY per 
case
DALY  per 
100.000
Austria 998 67.5 - 67.5 45 702.2 769.8 0.8 9.4
Belgium 1,153 78.0 - 78.0 - - - - -
Cyprus2 34 13.7 - 13.7 3 102.8 116.5 3.4 15.7
Czech Republic 1,075 146.1 - 146.1 75 1,274.0 1,420.1 1.3 13.9
Denmark 401 27.1 - 27.1 - - - - -
Estonia 579 78.0 - 78.0 98 2,779.2 2,857.2 4.9 211.8
Finland 368 25.1 - 25.1 75 808.2 833.2 2.3 15.9
France1 5,662 383.0 - 383.0 959 10,412.0 10,795.0 1.9 17.4
Germany 6,584 446.1 - 446.1 470 6,979.8 7,425.9 1.1 9.0
Greece 720 49.0 - 49.0 91 1,222.7 1,271.6 1.8 11.5
Hungary 2,315 314.3 - 314.3 300 6,156.2 6,470.5 2.8 64.0
Ireland 433 29.2 - 29.2 37 491.2 520.5 1.2 12.8
Italy 4,292 290.0 - 290.0 - - - - -
Latvia 1,593 215.3 - 215.3 202 5,623.4 5,838.7 3.7 252.4
Lithuania 2,636 356.9 - 356.9 325 8,684.2 9,041.2 3.4 263.2
Luxembourg 41 2.7 - 2.7 1 17.2 19.9 0.5 4.4
Malta 16 6.6 - 6.6 1 7.0 13.5 0.8 3.4
Netherlands 1,274 85.8 - 85.8 75 1,011.9 1,097.7 0.9 6.7
Poland 9,632 1,306.8 - 1,306.8 897 19,057.3 20,364.1 2.1 53.3
Portugal 3,846 258.6 - 258.6 328 5,924.8 6,183.4 1.6 58.9
Slovakia 816 111.0 - 111.0 - - - - -
Slovenia 278 37.7 - 37.7 20 394.8 432.5 1.6 21.7
Spain 7,684 518.6 - 518.6 459 6,974.8 7,493.4 1.0 17.6
Sweden1 479 32.3 - 32.3 57 483.4 515.7 1.1 5.7
United Kingdom 7,765 522.7 - 522.7 478 7,962.4 8,485.2 1.1 14.2
Iceland 9 0.6 - 0.6 5 33.0 33.6 3.6 11.5
Liechtenstein - - - - - - - - -
Norway 310 20.8 - 20.8 48 398.6 419.5 1.4 9.1
Note incidence = mean # of cases 2003-2005 (data EuroTB)
mortality = mean # of deaths 2003-2004 (data Eurostat/WHO)
YLD compl. = multi-drug resistant tuberculosis (MDR-TB) not taken into account in baseline scenario
- = no data available
1 = mortality data 2003 only
2 = mortality data 2004 only
Morbidity Mortality DALY per year
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The incidence of tuberculosis is difficult to determine, tuberculosis cases are mostly 
underreported.85 However no alternative estimates were available. In the baseline scenario 
multidrug-resistant tuberculosis was not included as complication. The duration and severity 
of MDR-TB were not available in other disease burden studies and the number of MDR-TB 
cases was only available for a limited number of countries. In scenario analysis the effect of 
MDR-TB has been addressed (section 10.3). 
 
10.3 Scenario analysis 
 
The disease burden in the pilot baseline scenario is close to the estimate of the Global Burden 
of Disease study (2002) (Figure 10.2). Another indication that the baseline scenario is a rather 
good estimate is that the Public Health Status and Forecast studies for the Netherlands 
estimated the Dutch disease burden for 2003 on 1,065 compared to 1,098 DALYs in the pilot 
baseline scenario. 
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Figure 10.2 Comparison baseline scenario pilot for tuberculosis with Global Burden of Disease 
study 
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Figure 10.3 shows the results of a scenario analysis for the Netherlands. In scenario 2 
multidrug-resistant tuberculosis has been included based on the assumption that the duration 
is two years and the severity can be compared with a terminal illness (severity weight = 0.93). 
The effect on the morbidity estimate is small because in the Netherlands the mean number of 
MDR-TB cases in the period 2003-2005 was small (n=5). In the Baltic States, where more 
MDR-TB cases are reported, the effect is more important (Figure 10.4). However the total 
disease burden for tuberculosis remains mainly dominated by mortality, even if multidrug-
resistant tuberculosis is taken into account. 
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Figure 10.3 Scenario analysis tuberculosis for the Netherlands 
 
10.4 Discussion and recommendations 
 
The disease burden estimate of the pilot baseline scenario is comparable with results of other 
studies. Especially for countries with a considerable number of multidrug-resistant 
tuberculosis cases, MDR-TB should be included in the disease burden estimate of 
tuberculosis.  
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Figure 10.4 Comparison morbidity (YLD) baseline scenario pilot for tuberculosis with scenario 2 
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11. Comparison between diseases 
 
Disease burden is a composite measure which includes not only incidence and mortality data 
but also the severity and duration of a disease. Figure 11.1 highlights the importance of 
taking disease burden estimates into consideration in guiding public health policy and 
actions. Based on incidence data individually, the foodborne diseases cause relatively the 
greatest burden, while mortality data indicate the relatively high burden of tuberculosis. 
Disease burden (DALYs) shows a quite different picture with a relative high burden for HIV-
infection and tuberculosis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.1 Relative burden of the seven selected diseases based on different indicators: 
- incidence (mean number of reported new cases per year in the period 2003-2005) 
- mortality (mean number of reported deaths per year in the period 2003-2004) 
- disease burden (DALYs per year based on above mentioned incidence and mortality) 
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campylobacteriosis (sum 20 countries)
infection with enterohaemorrhagic E. coli
(sum 20 countries)
salmonellosis (sum 23 countries)
tuberculosis (sum 23 countries)
Disease burden (DALYs per year per 100,000 population)
YLD acute YLD complications YLL
-> ranges from 0.8 in Portugal to 11.4 in Luxembourg
-> ranges from 0 in a number of countries to 6.5 in Malta
-> ranges from 0.8 in Czech Republic to 387.6 in Portugal
-> ranges from 0 in Cyprus to 27.6 in Czech Republic
-> ranges from 0 in Cyprus to 8.7 in Czech Republic
-> ranges from 0.4 in Portugal  to 19.1 in Czech Republic
-> ranges from 3.4 in Malta to 263.2 in Lithuania
In Figure 11.2 an estimate of the total disease burden per 100,000 population for the seven 
selected diseases is shown, for those countries for which YLD and YLL and DALY could be 
calculated. Because the number of countries for which the disease burden could be 
calculated, differs for each disease, a comparison between the diseases could be biased. 
However Figure V.1, based on the 12 countries for which the disease burden could be 
calculated for all diseases, shows a quite similar picture (see Appendix V). Figure V.2 
(Appendix V) shows the same picture as Figure 11.2 but in this figure all components of the 
DALY were included irrespective if one component is missing (for example: for HIV Spain 
is not included in Figure 11.2 because the total disease burden could not be calculated, in 
Figure V.2  for Spain the YLD of AIDS and the YLL is included). 
Figure 11.2 Sum of disease burden per 100,000 population of all countries for which data are 
available for at least one disease (for each disease number of countries is different) 
(Table 3.1 shows per disease which countries could not be included) 
 
Although the absolute numbers in the three pictures are different, the ranking between 
diseases does not change. All three pictures show that HIV-infection and tuberculosis have 
the highest disease burden in Europe but scenario analysis suggested that the disease burden 
of influenza is seriously underestimated. Measles has the lowest disease burden. The results 
of this comparison need to be considered with care because of the limitations of both data 
availability as well as data quality that are described in Chapter 3.  
Within each country the ranking can be different. However, in most countries HIV-infection 
and tuberculosis are responsible for the highest disease burden (in Western Europe HIV-
infection  is more often on top, in Eastern Europe tuberculosis) and measles for the lowest 
disease burden. For most diseases mortality has more effect on the disease burden estimate 
than morbidity, for the foodborne diseases morbidity (mainly complications) plays a more 
important role. However, scenario analysis has suggested that both morbidity and in 
particular reported mortality for foodborne diseases are likely to be underestimated. 
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12. General conclusions and recommendations  
 
12.1 Conclusions 
Potential of disease burden estimates for guiding public health policy and actions 
This pilot study reports preliminary estimates of the disease burden of a number of infectious 
diseases in the Europe, based on generally available data. The study makes clear that the 
relative burden of diseases as measured by disease burden is quite different compared to the 
relative burden as measured by just incidence or mortality data. Taking into account the 
limitations of this pilot in data availability and quality, it was found that (based on data for 
2003-2005 when available) the disease burden in Europe is estimated to be highest for HIV-
infection and tuberculosis, followed by campylobacteriosis, influenza and salmonellosis, and 
was lowest for measles and EHEC-infection. Scenario analysis limited to the Netherlands 
suggested that this ranking is not likely to be affected by better data. However, the relative 
burden of influenza is likely to increase. These results are in line with the expectations in 
advance: because HIV-infection and tuberculosis are chronic diseases, the disease burden was 
expected to be higher compared to the disease burden of the more acute diseases (i.e. 
measles). 
 
There are considerable differences between the burden of specific diseases across Europe. 
Most notable are a high disease burden (per 100,000 inhabitants) of HIV/AIDS in Portugal, 
Estonia and France (Spain had a high mortality burden but did not report the incidence of 
HIV-infections), of campylobacteriosis, EHEC-infection and salmonellosis in the Czech 
Republic, of salmonellosis in Slovenia and of tuberculosis in the Baltic States (Estonia, 
Latvia and Lithuania), Hungary, Portugal and Poland. This may partly be due to differences 
in reporting systems but will also be due to true differences in disease incidence between 
countries. If not corrected for underreporting, disease burden estimates are not very 
appropriate for comparison between countries and suffer from the same limitations as 
reported incidence. 
 
Estimates in this pilot study for the burden of measles, HIV/AIDS and tuberculosis are 
similar to those presented by the Global Burden of Disease (GBD) Study (WHO) and the 
Dutch Public Health Status and Forecast (PHSF) studies. Other infectious diseases evaluated 
in this pilot were not included in the GBD study and therefore this pilot gives added value. 
The PHSF study provided a higher burden of influenza, mainly due to higher morbidity 
estimates. Special studies at RIVM on the enteric pathogens also presented higher estimates. 
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The current disease burden reflects the balance between threats and the effectiveness of 
preventive measures. A low burden stresses the need for the continued support of these 
strategies. A high burden indicates the need for additional interventions. Disease burden 
estimates provide an integrated representation of the burden of infectious diseases. However, 
for priority setting other factors, such as threats and trends, costs and perception should be 
taken into account as well. For example, a recent study in the Netherlands has shown that on 
a population of 16 million in 2004 the annual costs for campylobacteriosis were € 22.3 
million, for salmonellosis € 8.8 million, for norovirus € 25.0 million and for rotavirus € 21.7 
million.9 
 
Exploration of data availability and quality 
Considerable limitations with regard to both data availability and data quality were 
encountered. Major limitations in data availability were: 
• inconsistent morbidity and/or mortality by some countries and/or for some years; 
• very limited information on the age-distribution of morbidity for most diseases; 
• no reporting of the incidence of complications and chronic sequelae; 
• no consistent set of severity weights available. 
 
Major limitations with regard to data quality were: 
• no information on underreporting of morbidity and mortality; 
• no information on possible variation between countries of the duration, severity and rate of 
complications and chronic sequelae; 
• differences between reports from different sources (national, Eurostat and WHO). 
 
The baseline results of this study were not adjusted for under-reporting. Scenario analysis has 
mainly focused on the limitations of incidence data. Based on Dutch results, it is concluded 
that the currently presented data may significantly underestimate the burden of infectious 
diseases in Europe. Underestimation is particularly a problem for: 
• influenza due to underreporting of morbidity and to a lesser extent of mortality; 
• HIV/AIDS due to incomplete information on the long-term outcomes of current infections; 
• enteric diseases (campylobacteriosis, EHEC-infection and salmonellosis) due to 
underreporting of both morbidity and mortality. 
Estimates of the burden of measles and tuberculosis appear to be less uncertain. Other data 
limitations were not evaluated in this pilot study due to limitations in time and resources. 
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12.2 Recommendations 
 
Disease burden (DALYs) calculations should be extended to other infectious diseases as well, 
because this composite measure gives more insight in burden than incidence or mortality data 
on its own. A full burden of disease study is recommended and would benefit from an 
approach that combines and triangulates several methods of investigation, including 
epidemiological modelling. In this short term pilot pragmatic choices had to be made, a full 
study should include a systematic and critical review on other disease burden estimates and 
on aspects like most suitable data sources, extent of underreporting, severity weights, 
outcome trees etcetera for each of the diseases under study.  Furthermore there needs to be 
general agreement on methodological issues discussed in Chapter 2 like using a standard life 
table instead of the European life expectancy (that changes over time) or showing both 
discounted and undiscounted results in the future. Where possible a full burden of disease 
study should join other international efforts in this field (i.e. the WHO update of the Global 
Burden of Disease for the year 2004). With regard to priority setting, besides disease burden 
other aspects such as economical costs or outbreak potential should also be taken into 
account. 
 
In order to obtain better insight in the epidemiology of infectious diseases in general and in 
the disease burden in particular, the following recommendations are made: 
• improve the completeness and consistency of reporting of the incidence of morbidity and 
mortality in Europe, including information on the age-distribution; 
• conduct cohort studies on the incidence of complications and chronic sequelae, including 
possible variability between countries and factors associated with that variability; 
• conduct studies addressing sources of underreporting of morbidity and mortality in order 
to calibrate the data and to decrease inconsistencies in reporting between countries; 
• improve quantification of the mortality risks due to infectious diseases by cohort-studies; 
• integrate mathematical modelling to better understand the current and future burden, in 
particular for the HIV/AIDS epidemic including the impact of HAART; 
• promote standardized data collection on disease severity and duration across Europe; 
• conduct studies on severity weights and obtain consensus on the protocols for such 
studies, including national differences; 
• develop a standardized approach to value choices inherent in disease burden calculations. 
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Appendix I List of communicable diseases for EU 
surveillance 
Source: 
ANNEX I of Commission Decision 2000/96/EC of 22 December 1999 on the communicable diseases 
to be progressively covered by the Community network under Decision No 2119/98/EC of the 
European Parliament and of the Council. Amended by Decision 2003/534/EC. 
 
1. COMMUNICABLE DISEASES AND SPECIAL HEALTH ISSUES TO BE 
PROGRESSIVELY COVERED BY THE COMMUNITY NETWORK 
1.1. For the diseases/health issues listed below, surveillance within the Community 
network will be performed by standardised collection and analysis of data in a way 
that will be determined for each disease/health issue when specific Community 
surveillance networks are put in place. 
 
2. DISEASES 
2.1. Diseases preventable by vaccination 
1. Diphtheria 
2. Infections with haemophilus influenza group B 
3. Influenza 
4. Measles 
5. Mumps 
6. Pertussis 
7. Poliomyelitis 
8. Rubella 
9. Smallpox (added by Commission Decision No 2003/534/EC) 
10. Tetanus (added by Commission Decision No 2003/534/EC) 
2.2.  Sexually transmitted diseases 
11. Chlamydia infections 
12. Gonococcal infections 
13. HIV-infection 
14. Syphilis 
2.3. Viral hepatitis 
15. Hepatitis A 
16. Hepatitis B 
17. Hepatitis C 
2.4. Food- and water-borne diseases and diseases of environmental origin 
18. Anthrax (added by Commission Decision No 2003/534/EC) 
19. Botulism 
20. Campylobacteriosis 
21. Cryptosporidiosis 
22. Giardiasis 
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23. Infection with enterohaemorrhagic E.coli 
24. Leptospirosis 
25. Listeriosis 
26. Salmonellosis 
27. Shigellosis 
28. Toxoplasmosis 
29. Trichinosis 
30. Yersinosis 
2.5. Other diseases 
2.5.1. Diseases transmitted by non-conventional agents 
31. Transmissible spongiform encephalopathies variant (CJD) 
2.5.2. Air-borne diseases 
32. Legionellosis 
33. Meningococcal disease 
34. Pneumococcal infections 
35. Tuberculosis 
2.5.3. Zoonoses (other than in 2.4) 
36. Brucellosis 
37. Echinococcosis 
38. Q-Fever (added by Commission Decision No 2003/534/EC) 
39. Rabies 
40. Tularaemia (added by Commission Decision No 2003/534/EC) 
2.5.4. Serious imported diseases 
41. Cholera 
42. Malaria 
43. Plague 
44. Viral haemorrhagic fevers 
 
3. SPECIAL HEALTH ISSUES 
45. Nosocomial infections 
46. Antimicrobial resistance 
 
4. EMERGING DISEASES 
47. SARS 
48. West-Nile virus 
49. Avian influenza 
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Appendix II List of countries 
 
The 25 EU Member States (situation 2006)*: 
 
Austria  Estonia  Hungary  Luxembourg  Slovakia 
Belgium  Finland  Ireland  Malta  Slovenia 
Cyprus France  Italy  the Netherlands  Spain 
Czech Republic Germany  Latvia  Poland  Sweden  
Denmark  Greece  Lithuania  Portugal  United Kingdom 
 
* Bulgaria and Romania joined the EU in January 2007 but are not included in this report 
 
The EEA/EFTA Countries: 
 
Iceland 
Liechtenstein 
Norway 
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Appendix III Life expectancy 
Life expectancy at the average age of death within each age interval (used in this study) 
 
 
European 
life expectancy 
2004* 
 Standard 
life expectancy 
West Level 26** 
Age 
(years) 
Average 
age at death Total Males Females 
 
Males Females 
0 0.1 78.57 75.48 81.56  79.94 82.43 
1-4 2.6 76.43 73.36 79.40  77.77 80.28 
5-9 7.5 71.59 68.53 74.56  72.89 75.47 
10-14 12.5 66.64 63.58 69.60  67.91 70.51 
15-19 17.5 61.72 58.68 64.65  62.93 65.55 
20-24 22.5 56.87 53.88 59.73  57.95 60.63 
25-29 27.5 52.04 49.12 54.82  52.99 55.72 
30-34 32.5 47.21 44.36 49.92  48.04 50.83 
35-39 37.5 42.43 39.64 45.06  43.10 45.96 
40-44 42.5 37.72 35.01 40.25  38.20 41.13 
45-49 47.5 33.14 30.54 35.54  33.38 36.36 
50-54 52.5 28.73 26.28 30.96  28.66 31.68 
55-59 57.5 24.48 22.20 26.48  24.07 27.10 
60-64 62.5 20.40 18.35 22.13  19.65 22.64 
65-69 67.5 16.56 14.78 17.96  15.54 18.32 
70-74 72.5 13.03 11.58 14.06  11.87 14.24 
75-79 77.5 9.89 8.80 10.55  8.81 10.59 
80-84 82.5 7.16 6.45 7.53  6.34 7.56 
85+ 90.0 4.01 3.63 4.20  3.54 4.25 
Life expectancy at the beginning of the age interval 
 
European 
life expectancy 
2004* 
 Standard 
life expectancy 
West Level 26** 
Age 
(years) Total Males Females 
 
Males Females 
0 78.63 75.54 81.63  80.00 82.50 
1 78.00 74.93 80.97  79.36 81.84 
5 74.07 71.00 77.04  75.38 77.95 
10 69.11 66.05 72.08  70.40 72.99 
15 64.16 61.10 67.11  65.41 68.02 
20 59.28 56.27 62.19  60.44 63.08 
25 54.45 51.50 57.28  55.47 58.17 
30 49.62 46.74 52.37  50.51 53.27 
35 44.80 41.99 47.48  45.57 48.38 
40 40.05 37.30 42.63  40.64 43.53 
45 35.38 32.72 37.87  35.77 38.72 
50 30.89 28.35 33.22  30.99 33.99 
55 26.57 24.20 28.69  26.32 29.37 
60 22.38 20.20 24.26  21.81 24.83 
65 18.42 16.49 19.99  17.50 20.44 
70 14.71 13.08 15.92  13.58 16.20 
75 11.36 10.09 12.19  10.17 12.28 
80 8.42 7.52 8.92  7.45 8.90 
* Calculation based on total mortality and average population EU-25 in 2004 (data Eurostat) 
** Life expectancy used in Global Burden of Disease study  
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Appendix IV Data and assumptions baseline estimates 
of disease burden 
Table IV.1 Influenza: incidence, duration and severity weight for each outcome (see section 4.1) 
Outcome Estimate Source and assumptions 
Acute illness with fever   
- incidence reported cases number of sentinel and non-sentinel respiratory 
specimens tested positive for influenza A or B based 
on annual reports of European Influenza Surveillance 
Scheme (EISS); mean number of the three influenza 
seasons 2002/200386, 2003/200487 and 2004/200527 
- duration 1 year severity weight based on annual profile24 
- severity weight 0.01 annual profile (1 year with 2 weeks influenza)24 
Otitis media   
- incidence 0.65% of influenza 
cases 
0.0065 * influenza incidence31 
- duration 0.08 year Global Burden of Disease23 
- severity weight 0.023 (all ages) Global Burden of Disease17 
Deafness (due to otitis media)   
- incidence 0.3/5,067 otitis media 
cases 
Global Burden of Disease23; 0.000059206 * otitis 
media incidence (in EME* incidence rate otitis media 
is 5,067 per 100,000 and incidence rate deafness due 
to otitis media is 0.3 per 100,000) 
- duration chronic full life expectancy because age is unknown and 
otitis media occurs more often in children 
- severity weight 00-04 year 0.175 
05-14 year 0.169 
15-44 year 0.168 
45-59 year 0.168 
60+ year 0.168 
Global Burden of Disease17; if age unknown we 
choose severity weight 0.168 (same for ages 15 years 
and older) 
 
Pneumonia   
- incidence 0.36% of influenza 
cases 
0.0036 * influenza incidence31 
- duration EME* 0.02 year 
FSE** 0.02 year 
MEC*** 0.03 year 
Global Burden of Disease23; duration of lower 
respiratory infections in general (pneumonia not 
available) 
- severity weight 00-04 year 0.280 
05-14 year 0.280 
15-44 year 0.276 
45-59 year 0.276 
60+ year 0.280 
Global Burden of Disease17; severity weight of lower 
respiratory infections in general (pneumonia not 
available); 
if age unknown we choose severity weight 0.278 
(mean 0.276 and 0.280) 
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Table IV.2 Measles: incidence, duration and severity weight for each outcome (see section 5.1) 
Outcome Estimate Source and assumptions 
Acute illness with fever   
- incidence reported cases data Eurostat, mean 2003-2005 
- duration 0.04 year Global Burden of Disease23 
- severity weight 0.152 (all ages) Global Burden of Disease17 
Otitis media   
- incidence 5-10% of measles cases 0.075 * measles incidence28 
- duration 0.08 year Global Burden of Disease23 
- severity weight 0.023 (all ages) Global Burden of Disease17 
Deafness (due to otitis media)   
- incidence 0.3/5,067 per otitis 
media case 
Global Burden of Disease23; 0.000059206 * otitis 
media incidence (in EME* incidence rate otitis media 
is 5,067 per 100,000 and incidence rate deafness due 
to otitis media is 0.3 per 100,000) 
- duration chronic full life expectancy because in general measles 
incidence is highest in youngest age groups 
- severity weight 00-04 year 0.175 
05-14 year 0.169 
15-44 year 0.168 
45-59 year 0.168 
60+ year 0.168 
Global Burden of Disease17; if age unknown we 
choose severity weight 0.172 (mean 00-04 year and 
05-14 year; in general incidence of measles is highest 
in the youngest age groups) 
 
Pneumonia   
- incidence 1-5% of measles cases 0.03 * measles incidence28 
- duration EME* 0.02 year 
FSE** 0.02 year 
MEC*** 0.03 year 
Global Burden of Disease23; duration of lower 
respiratory infections in general (pneumonia not 
available) 
- severity weight 00-04 year 0.280 
05-14 year 0.280 
15-44 year 0.276 
45-59 year 0.276 
60+ year 0.280 
Global Burden of Disease17; severity weight of lower 
respiratory infections in general (pneumonia not 
available), if age unknown we choose severity weight 
0.280 (in general incidence of measles is highest in 
the youngest age groups) 
 
Encephalitis   
- incidence 0.1% of measles cases 0.001 * measles incidence28 
- duration 0.08 year Global Burden of Disease23; duration bacterial 
meningitis (encephalitis not available) 
- severity weight 00-04 year 0.616 
05-14 year 0.616 
15-44 year 0.613 
45-59 year 0.613 
60+ year 0.613 
Global Burden of Disease17; severity weight of 
bacterial meningitis and Japanese encephalitis 
(encephalitis not available), if age unknown we 
choose severity weight 0.616  (in general incidence 
of measles is highest in the youngest age groups) 
 
Sequelae encephalitis   
- incidence 0.255 per encephalitis 
case 
0.255 * encephalitis incidence (mortality 10-20% and 
morbidity 20-40% of patients who recovered -> 
0.255 per measles encephalitis case) 
- duration chronic full life expectancy because in general incidence of 
measles is highest in the youngest age groups 
- severity weight 00-04 year 0.334 
05-14 year 0.334 
15-44 year 0.334 
Global Burden of Disease17; severity weight of motor 
deficit bacterial meningitis and neurological sequelae 
Japanese encephalitis (sequelae encephalitis not 
available), if age unknown we choose severity weight 
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45-59 year 0.337 
60+ year 0.390 
0.334  (in general incidence of measles is highest in 
the youngest age groups) 
 
Subacute sclerosing 
panencephalitis (SSPE) 
  
- incidence 0.6-2.2 per 100,000 
measles cases 
0.000014 * measles incidence54 
- duration 0.75 year duration of 9 months 88 
- severity weight 0.93 (all ages) severity weight of terminal disease, end stage (SSPE 
not available)24 
 
Table IV.3 HIV-infection: incidence, duration and severity weight for each outcome 
(see section 6.1) 
Outcome Estimate Source and assumptions 
Symptomatic infection   
- incidence reported cases data EuroHIV, mean 2003-2005 
- duration EME* 10 year 
FSE**   7 year 
MEC***   7 year 
Global Burden of Disease23; duration before 
introduction of HAART, in the age group 0-4 year 
average duration is less but there is no specific 
incidence information on this age group and the 
incidence in younger age groups is small 
- severity weight 00-04 year 0.123 
05-14 year 0.123 
15-44 year 0.136 
45-59 year 0.136 
60+ year 0.136 
Global Burden of Disease17; severity weight before 
introduction of HAART, if age unknown we choose 
severity weight 0.136 (incidence in younger age 
groups is small) 
 
AIDS   
- incidence notified cases EuroHIV data EuroHIV, mean 2003-2005 
- duration EME* 2 year 
FSE** 1 year 
MEC*** 1 year 
Global Burden of Disease23; duration before 
introduction of HAART, 
in the age group 0-4 year the average duration in FSE 
and MEC is 0.5 year 
- severity weight 0.505 (all ages) Global Burden of Disease17; severity weight before 
introduction of HAART 
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Table IV.4 Campylobacteriosis: incidence, duration and severity weight for each outcome 
(see section 7.1) 
Outcome Estimate Source and assumptions 
Gastroenteritis   
- incidence reported cases data Eurostat, mean 2003-2005 
- duration 9.9 days = 0.027 year weighted mean of duration for cases visiting GP 
(9.72 days) and hospitalized (14.39 days); 
assumption: the reported incidence = patients that at 
least have visited GP9 
- severity weight 0.393 9 
Reactive arthritis (ReA)   
- incidence 0.16 per case Netherlands 2004: 1,000 cases per 6,285 laboratory-
confirmed Campylobacteriosis cases9, 89 
- duration 222 days = 0.61 year 9 
- severity weight 0.14 weighted mean of severity weights for cases not 
visiting GP (0.127), visiting GP (0.21) and 
hospitalized (0.37) = 0.149 
Guillain Barré Syndrome (GBS), 
    1st year 
  
- incidence 0.009 per case Netherlands 2004: 59 cases per 6,285 laboratory-
confirmed Campylobacteriosis cases9, 89 
- duration 1 year 90 
- severity weight 0.25 weighted mean of severity weights (1st year) for mild 
and severe GBS = 0.2590 
Guillain Barré Syndrome (GBS), 
     following years 
(long term sequela) 
  
- incidence 0.009 per case same as GBS 1st year9 
- duration 29.26 year weighted mean of duration mild and severe GBS = 
30.26 year – 1 (first year) 90 
- severity weight 0.16 weighted mean of severity weights (following years) 
for mild and severe GBS (including full recovery) = 
0.1690 
Inflammatory Bowel Disease 
(IBD) 
  
- incidence 0.0035 per case Netherlands 2004: 22 cases per 6,285 laboratory-
confirmed Campylobacteriosis cases9, 89 
- duration 44.36 year (total) life long -> mean life expectancy based on age 
distribution cases visiting GP9 
- severity weight 0.26 9 
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Table IV.5 EHEC-infection: incidence, duration and severity weight for each outcome 
(see section 8.1) 
Outcome Estimate Source and assumptions 
Watery diarrhoea (WD), 
haemorrhagic colitis (HC) 
  
- incidence reported cases data Eurostat, mean 2003-2005 
- duration 5.6 days = 0.015 year 7 
- severity weight 0.393 9 
Haemolytic-uraemic syndrome 
(HUS), including end-stage 
renal disease (ESRD) 
  
- incidence 0.5 per case Netherlands 2004: 21 cases9 per 42 cases reported to 
Eurostat 
- duration  model indicates 22.7 YLD for 21.7 cases -> 1.05 
YLD per HUS case91 
- severity weight  model indicates 22.7 YLD for 21.7 cases -> 1.05 
YLD per HUS case91 
 
Table IV.6 Salmonellosis: incidence, duration and severity weight for each outcome 
(see section 9.1) 
Outcome Estimate Source and assumptions 
Gastroenteritis   
- incidence reported cases data Eurostat, mean 2003-2005 
- duration 11.2 days = 0.031 year weighted mean of duration for cases visiting GP 
(10.65 days) and hospitalized (16.15 days); 
assumption: the reported incidence = patients that at 
least have visited GP9 
- severity weight 0.393 9 
Inflammatory Bowel Disease 
(IBD) 
  
- incidence 0.003 per case Netherlands 2004: 7 cases per 2,573 laboratory-
confirmed Campylobacteriosis cases9, 89 
- duration 50.52 year (total) life long -> mean life expectancy based on age 
distribution cases visiting GP9 
- severity weight 0.26 9 
Reactive arthritis (ReA)   
- incidence 0.18 per case Netherlands 2004: 460 cases per 2,573 laboratory-
confirmed Campylobacteriosis cases9, 89 
- duration 0.61 year 222 days9 
- severity weight 0.15 weighted mean of severity weights for cases not 
visiting GP (0.127), visiting GP (0.21) and 
hospitalized (0.37) = 0.159 
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Table IV.7 Tuberculosis: incidence, duration and severity weight for each outcome 
(see section 10.1) 
Outcome Estimate Source and assumptions 
Latent tuberculosis  not taken into account because incidence, duration 
and severity is unknown 
(Extra)pulmonary tuberculosis   
- incidence reported cases data EuroTB, mean 2003-2005; rough proxy of 
incidence: a proportion of the cases would have had 
tuberculosis in the past 
- duration EME* 0.25 year 
FSE** 0.50 year 
MEC*** 1.50 year 
Global Burden of Disease23; no difference between 
pulmonary and extrapulmonary tuberculosis 
- severity weight 00-04 year 0.294 
05-14 year 0.294 
15-44 year 0.264 
45-59 year 0.274 
60+ year 0.274 
Global Burden of Disease17; no difference between 
pulmonary and extrapulmonary tuberculosis, if age 
unknown we choose severity weight 0.274 
 
Multidrug-resistant tuberculosis  not taken into account in baseline estimate because 
duration and severity is unknown 
- incidence reported cases EuroTB data EuroTB, mean 2003-2005 (limited number of 
countries) 
 
Table IV.8 All diseases: mortality and life expectancy 
All diseases Estimate Source and assumptions 
- mortality reported deaths data Eurostat/WHO, mean 2003-2004 (2005 not yet 
available for many countries)  
ICD-10 codes: influenza (J10-J11), measles 
(B05+A81.1), HIV-infection (B20-B24), 
campylobacteriosis (A04.5), EHEC-infection 
(A04.3), salmonellosis (A02) and tuberculosis (A15-
A19+B90); 
assumption 1: if a country has reported deaths for a 
specific year according to ICD-10 in general but the 
number of deaths for a specific disease is missing, we 
assumed that zero deaths have been reported for that 
specific disease; 
assumption 2: in case of differences between Eurostat 
and WHO, we used data Eurostat; 
- life expectancy life expectancy  
Europe 2004 
data Eurostat European Union 2004 (25 countries); 
own calculation of European life expectancy 2004 
based on total number of deaths and average 
population in Europe in 2004 (latest data available) 
 
* EME = Established market economies (all other countries in the project than FSE and MEC, see below )  
** FSE = Formerly socialist economies of Europe (Czech Republic, Estonia, Hungary, Latvia, Lithuania, 
Poland, Slovakia, Slovenia) 
*** MEC = Middle Eastern crescent (Cyprus, Malta) 
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Appendix V Figures on comparison between diseases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure V.1 Sum of disease burden per 100,000 population of 12 countries for which data is 
available for all diseases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure V.2 Sum of disease burden per 100,000 population of all countries for which data is 
available, also for countries with missing DALY components 
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